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This work describes the use of second harmonic generation (SHG) and 
ultraviolet-visible sum-frequency generation (UV-Vis SFG) to directly detect ligand-
protein recognitions and drug-membrane associations. First, SHG spectroscopy was 
employed to detect protein-ligand binding for several model systems: avidin, streptavidin, 
neutrAvidinTM and anti-biotin antibody binding to biotin. The equilibrium binding 
affinities of these model systems were measured and compared with those values 
reported in literature to validate the ability of SHG to detect protein-ligand interactions 
without any chemical modification. Furthermore, the energetics of the protein-ligand 
binding and the protein nonspecific adsorption were evaluated to provide useful 
information about these protein-ligand pairs which are commonly used in many 
bioanalytical applications.  
Next, UV-Vis SFG spectroscopy was developed and utilized to detect drug-lipid 
membrane association for four drugs: ibuprofen, azithromycin, tetracaine, and tolnaftate. 
Drug association was measured on planar supported lipid bilayers composed of 1,2-
dioleoyl-sn-glycero-3-phosphocholine. The drugs' equilibrium association constants were 
obtained and correlated with the drugs' partition coefficients in the membrane-water 
system. Furthermore, the drug surface excess in the lipid membrane was quantitatively 
determined using the combination of the UV-Vis SFG and the bulk partition coefficient. 
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It was shown that UV-Vis SFG is a powerful and novel technique to directly measure the 
association of drugs to a lipid membrane without chemical modification.  
Finally, SHG imaging was employed in the label-free detection of the interactions 
between tetracaine and a multicomponent planar supported lipid bilayer array (MLBA). 
The MLBAs allowed the effects of lipid phase and cholesterol content on tetracaine 
binding to be examined simultaneously. Additionally, tetracaine binding at different 
charge states and the effect of the charged lipids were investigated. The maximum 
surface excess of tetracaine in the lipid bilayers was also determined. This demonstrates 
that SHG imaging is a sensitive technique which can directly image and quantitatively 
measure the association of tetracaine in a high-throughput manner. 
This work has demonstrated that SHG and UV-Vis SFG are valuable alternatives 
in detection of biomolecular interactions at a lipid bilayer surface. The use of SHG or 
UV-Vis SFG imaging in combination with the MLBAs offer potential applications in 




ABSTRACT  ...................................................................................................................... iii   
LIST OF TABLES  ........................................................................................................... vii 
ACKNOWLEDGEMENTS  .............................................................................................. ix 
1 INTRODUCTION  ..................................................................................................1  
 1.1       References  ...................................................................................................7 
2. GENERAL PRINCIPLES OF SECOND HARMONIC GENERATION  ............11 
 2.1       General Principles of SHG ........................................................................11 
 2.2       Summary  ...................................................................................................21 
 2.3       References  .................................................................................................23 
   
3.  INVESTIGATION OF BIOTIN BOUND PROTEIN-BIOTINYLATED        
LIPID INTERACTIONS WITH SECOND HARMONIC GENERATION  ........25  
 3.1       Introduction  ...............................................................................................25 
 3.2       Experimental  .............................................................................................29 
 3.3       Results and Discussion  .............................................................................37 
 3.4       Summary  ...................................................................................................56 
 3.5       References  .................................................................................................57 
4. GENERAL PRINCIPLES OF ULTRAVIOLET-VISIBLE SUM-     
FREQUENCY GENERATION  ............................................................................61 
 4.1       General Principles of SFG  ........................................................................61  
 4.2       Ultraviolet-Visible (UV-Vis) Sum-Frequency Generation  .......................67 
 4.3       Summary  ...................................................................................................73 
 4.4       References  .................................................................................................74 
5.  DETECTION OF DRUG-LIPID MEMBRANE INTERACTIONS WITH 
UV-VIS SUM-FREQUENCY GENERATION  ...................................................75 
 5.1       Introduction  ...............................................................................................75  
 5.2       Experimental  .............................................................................................80 
 5.3       Results and Discussion  .............................................................................84  
 vi 
 
 5.4       Summary  .................................................................................................107 
 5.5       References  ...............................................................................................107  
6.  HIGH-THROUGHPUT SCREENING OF DRUG-LIPID MEMBRANE 
INTERACTIONS VIA SECOND HARMONIC GENERATION            
IMAGING  ...........................................................................................................110 
 6.1       Introduction  .............................................................................................110 
 6.2       Experimental  ...........................................................................................114 
 6.3       Results and Discussion  ...........................................................................120   
 6.4       Summary  .................................................................................................159 
 6.5       References  ...............................................................................................160 








LIST OF TABLES 
Table Page 
                     
3.1 Measured intrinsic binding affinity and cooperativity coefficient for 
avidin, streptavidin, and neutrAvidinTM  ................................................................43 
3.2 Calculated intrinsic free energy, free energy due to protein-protein 
interactions, total free energy, and apparent binding affinity for avidin, 
streptavidin, and neutrAvidinTM  ............................................................................47 
4.1  Indices of refraction of fused silica and water at different wavelengths  ..............70 
5.1  Logarithm of partition coefficients of six ionized drugs in octanol-water 
and liposome membrane-water systems  ...............................................................85 
5.2  Logarithm of partition coefficients of five neutral drugs in octanol-
water and liposome membrane-water systems  .....................................................86  
5.3  Measured equilibrium association constant, square-root of maximum 
SFG intensity at surface saturation, and g values for various drugs  .....................93 
5.4  Partition coefficient in membrane-water system, transfer free energy, 
and adsorption free energy for various drugs  .......................................................94 
5.5 Maximum surface excess and limit of detection for various drugs  ....................102 
5.6  Measured equilibrium association constant, square-root of maximum 
SFG intensity at surface saturation, and g values for ibuprofen at 
different electrolyte concentrations  .....................................................................106 
6.1  Measured binding affinity of tetracaine to lipid bilayers at different 
temperatures  ........................................................................................................125 
6.2  Maximum surface excess of tetracaine in lipid bilayers  .....................................135  
6.3  Measured binding affinity of tetracaine to lipid bilayers containing 28 
mol % cholesterol at different temperatures  .......................................................140 
6.4  Maximum surface excess of tetracaine in lipid bilayers containing 28 
mol % cholesterol at different temperatures  .......................................................144 
 viii 
 
6.5  Free energy, enthalpy, and entropy of tetracaine binding to lipid 

















 I would like to acknowledge all those who have assisted and supported me during 
my graduate career at the University of Utah. Without their help and encouragement, this 
dissertation would not have been possible. 
 First, I would like to acknowledge Prof. John Conboy for his valuable guidance 
on my research project, willingness to help when needed, and his enthusiasm for research 
which truly motivated me. I appreciate the freedom provided by Prof. Conboy allowing 
me to try new ideas and troubleshoot the instruments in the lab which greatly 
supplemented my understanding.  
 I would also like to express my appreciation to my advisory committee members, 
Profs. Harris, Morse, Bartl and Herron, for their valuable critiques and reviews of my 
research. 
 I am grateful to all my colleagues for their help, support and friendship. In 
particular, Krystal Brown deserves my thanks for her suggestions and for proof-reading 
my manuscripts and dissertation. I am thankful to Krystal Sly, who teamed up with me on 
the protein project. We went through difficulties, frustration and finally excitement when 
the project had finished. Krystal Sly, thank you for your great effort, for taking the night 
shift for months and for being a good friend. I thank Kathryn Smith for assisting me with 
the use of the microspotter and for interesting discussions about the lipid microarray. My 
  x   
 
thanks also go to Drs. Jin Liu and Julie Rollins for showing me everything I needed to 
know when I first started to work in the lab.  
 I would like to thank the professional staff in the Chemistry Department for their 
help, especially, Ms. Margaret Beebe, our group secretary, who has always been helpful 
and supportive.  
 Last but not least is my deepest appreciation to my big family for their love and 
support. Mom and Dad, I thank you for your love, encouragement and sacrifice to make 
sure that I have always had the best things in my life. I am proud to be your daughter. 
Thanks to my sister, Thao, for being supportive and a good listener. I must mention the 
support from my brothers, Thanh and Son. My thanks to my parents-in-law for loving me 
as their own daughter. Thanks to Hieu, my brother-in-law, for his kindness and 
watchfulness. Special thanks go to my husband, Lam, for always being there for me. His 
love, support and companionship has made my life's journey more joyful and interesting.
 
 




Biomolecular interactions are the basis of all activities in living systems. For 
example, complex signal pathways for hormones and neurotransmitters are regularly 
initiated by the interactions between G protein coupled receptors (GPCRs) and ligands;1 
immune responses are mediated by antibody-antigen interactions;2,3 cell recognition and 
adhesion are related to protein-carbohydrate interactions;4-7 and pharmacological 
activities are often induced by drug-protein/drug-cell membrane interactions.8-10 The 
investigation and characterization of such biomolecular interactions would enhance our 
understanding of the mechanisms and functions of many biological activities. 
Consequently, there has been a significant effort to develop techniques which can more 
efficiently and accurately detect biomolecular interactions. Such detailed information 
would enable advancements in biosensing applications, such as more efficient medical 
diagnostic tools and pharmaceuticals. Biosensors are normally designed to detect a 
specific binding event between a ligand immobilized on a sensor surface and a 
biomolecule in solution. Development of these types of applications requires techniques 
capable of detecting biomolecular interactions at surfaces.  
Currently, biomolecular interactions are most commonly investigated by 
fluorescence where the biomolecule of interest is detected via a fluorescent probe.2,11-14 
Surface specific total internal reflection fluorescence (TIRF) is an extremely sensitive 
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technique that can detect interactions at the molecular level.15,16 However, the major 
drawback of fluorescence is that attaching a fluorescent probe can alter the native 
conformation and/or charge of the biomolecule and subsequently alter its binding 
properties.17 Even when the biomolecule has intrinsic fluorescence, photobleaching or 
self-quenching of the fluorophore is common and would also alter the observed 
binding.18,19 To circumvent these issues, label-free techniques such as surface plasmon 
resonance (SPR) and quartz crystal microbalance (QCM) have been utilized. SPR, an 
optical technique that quantifies the binding of biomolecules by detecting the 
corresponding  change in mass, has been used to detect drug-liposome interactions20,21 
and ligand-protein interactions.22-24 Similarly, QCM detects binding events through mass 
changes and has been used to detect proteins binding to a ligand immobilized on a sensor 
surface.25-27 Although SPR and QCM offer the advantage of label-free detection, these 
mass based techniques lack the chemical sensitivity of spectroscopic methods and are 
therefore limited in their applications. Raman scattering incorporated with confocal 
microscopy, another label-free technique, has been used in detection of drug-liposome 
interactions.28 The confocal microscopy allows Raman scattering from individual lipid 
vesicles to be detected, eliminating the contribution from the lipid matrix. As the Raman 
scattering signal is intrinsically weak, the technique requires a high laser power and long 
integration time.29  Additionally, the Raman signal is often saturated by fluorescence 
from the samples.29 Therefore, the limitation of these techniques makes it essential to 




    
 
Recently, the nonlinear optical spectroscopic techniques sum-frequency 
generation vibrational spectroscopy (SFVS) and second harmonic generation (SHG) have 
been used for biomolecular interactions at interfaces.30-41 Specifically, SFVS has been 
used to investigate structure and orientation of membrane protein/peptide associated in 
lipid membrane,30,34 and interactions between fibrinogen or blood coagulation factor and 
polymer surfaces.32,42 SHG has been applied to monitor protein adsorption at a 
solid/liquid interface,35,36 and peptide association to a lipid bilayer.37,38 It has also been 
successfully applied to image biological tissue,39 living cells,40 protein crystals, and chiral 
molecules adsorbed to lipid bilayer arrays.43 As coherent scattering processes that are 
independent of a direct electronic excitation or emission, SFG and SHG do not 
significantly suffer from photobleaching or phototoxicity as fluorescence does.40 
Furthermore, SFG and SHG possess the surface specificity, high sensitivity and 
spectroscopic selectivity (infrared for SFG and ultraviolet-visible for SHG) making them 
as attractive and powerful techniques to study biomolecular interactions.  
In this dissertation, the study of biomolecular interactions at lipid bilayer surfaces 
by SHG and SFG is presented.  The general principles of SHG are discussed in Chapter 2 
with a focus on the counter-propagating geometry. Next, the application of SHG 
spectroscopy in detecting biomolecular interactions is presented in Chapter 3. In 
particular, protein-ligand interactions are investigated using avidin, streptavidin, 
neutrAvidinTM and anti-biotin antibody binding to biotin ligand doped in a lipid bilayer. 
These protein-biotin complexes have been used as models for studying protein-ligand 
interactions which are normally investigated by fluorescence16,44,45 or SPR.24  The use of 
these particular protein-biotin models allow for a comparison between the results 
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obtained by SHG and previously published data to evaluate the utility of SHG as a 
method to study protein-ligand interactions. In addition to being used as the protein-
ligand models, avidin, streptavidin, neutrAvidinTM and anti-biotin antibody-biotin 
complexes are often used as linkers to capture biomolecules in biosensing applications.46-
58 Despite the fact that these complexes are used interchangeably, very little work to date 
has compared the specific and nonspecific affinities of avidin, streptavidin, 
neutrAvidinTM, and anti-biotin antibody to biotin at surfaces. The direct comparison 
presented in Chapter 3 offers new and useful information about the binding properties of 
complexes commonly used in a wide variety of bioanalytical applications. 
 To further demonstrate the ability of nonlinear optical spectroscopies in detection 
of biomolecular interactions, ultraviolet-visible (UV-Vis) SFG is implemented and used 
as an ultrasensitive technique in studying biomolecular interactions. In Chapter 4, the 
background of SFG is presented along with a discussion of UV-Vis SFG. UV-Vis SFG is 
able to probe electronic transitions in the deep UV region (π → π* and n → π* 
transitions). This enables the detection of a variety of biological species including 
aromatic amino acids, peptides, proteins and aromatic/double bond containing drugs. 
Since most drugs on the market target proteins embedded within cell membranes,59 any 
interaction between the drug and lipids surrounding the targeted proteins may influence 
the drug’s pharmacological activities.60,61 This makes the detection of drug-lipid 
membrane interactions of great interest. Conventionally, drug-membrane interactions 
have been studied using the equilibrium of the drug between water and 1-octanol, a 
molecule which mimics the lipid membrane.62-64 However, the thermodynamics of a lipid 
membrane, a roughly 50 Å thick bilayer composed of various phospholipids, proteins and 
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cholesterol, cannot be effectively characterized by the bulk thermodynamic properties of 
a homogenous liquid phase. While liposome based assays have been developed to more 
accurately model and study drug-membrane association,65-68 the use of planar supported 
lipid bilayers (PSLBs) offers the advantage of no separation step required as compared to 
the liposome based assays. In order to effectively and accurately study drug-lipid 
membrane interactions, a method with both great sensitivity and surface specificity is 
required. This combination would allow the direct detection of analytes with such low 
molecular weights without any chemical modification at the interfacial level without 
interference from solution phase species. It is shown in Chapter 5 that the UV-Vis SFG 
spectroscopy can be used to detect drug-lipid membrane interactions. The association 
constants of four different drugs including ibuprofen, azithromycin, tetracaine and 
tolnaftate into a lipid bilayer were measured. Furthermore, the surface excess of each 
drug in the lipid bilayers was accessible using the UV-Vis SFG measurements in 
combination with the partition coefficients of the drugs. Knowledge of the surface excess 
of the drug in the membrane is crucial as it determines the bioavailability of the drug to 
its target protein. The work presented in Chapter 5 demonstrates the ability of UV-Vis 
SFG to be used as a new powerful technique in detection of small molecules (drugs) 
association into a lipid bilayer.  
 There has been a significant effort to develop high-throughput screening methods 
for rapid and efficient detection of biomolecular interactions. High-throughput screening 
using microarray based assays for DNA69-71 and proteins67,68 allow multiple binding 
events to be detected in a single assay.  Such microarray assays have been successfully 
employed for the detection of DNA sequencing and antibody-antigen interactions. In 
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order to take advantage of the ability of microarray based assays to detect multiple 
binding events, in Chapter 6, a high-throughput detection method was developed to 
measure drug association into multicomponent lipid bilayer microarrays. The lipid 
bilayer microarray, created by a continuous flow microspotter, allowed the effects of lipid 
physical state and cholesterol content on the local anesthetic tetracaine binding to be 
examined simultaneously by second harmonic generation imaging. Additionally, the 
interactions between tetracaine and the lipid bilayer arrays at different charge states 
(protonated and neutral) of the drug and the effect of charged lipids were examined. The 
results illustrate that SHG imaging in combination with a lipid bilayer array has potential 
applications for high-throughput screening.  
The problems associated with labeling a biomolecule with a fluorescent probe 
have been the major driving force for the development of label-free methods. Surface 
specific SPR and QCM have received great attention because as mass-based techniques 
they can detect biomolecular interactions without chemical modification; however, the 
lack of spectroscopic sensitivity limits their applications. The nonlinear optical 
spectroscopic techniques, SHG and UV-Vis SFG possess surface specificity, 
spectroscopic sensitivity and the ability to be coupled with a lipid microarray to enable 
the direct detection of biomolecular interactions, i.e., protein-ligand and small molecule-
lipid membrane, in a high-throughput fashion. Furthermore, the SHG imaging provides a 
direct visualization of drug association into lipid membranes without chemical 
modification as required by the conventional fluorescence technique. The work presented 
in this dissertation demonstrates the potential use of SHG and UV-Vis SFG 
spectroscopy/imaging in protein and drug screening.   
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GENERAL PRINCIPLES OF SECOND HARMONIC GENERATION 
 Second harmonic generation (SHG) is a coherent second-order nonlinear optical 
process in which two photons at the same frequency ω are combined to generate a third 
photon at the frequency twice of the input frequency, 2ω. The process is only allowed in 
a noncentrosymmetric medium or at the interface between two centrosymmetric media. 
As the theory of second harmonic generation (SHG) have been previously described in 
depth,1,2 only the general principles of SHG will be presented in this chapter with a focus 
on the counter-propagating geometry which will be employed in the studies presented in 
Chapter 3 and 6.  
 SHG is the nonlinear conversion of two photons of frequency ω to a new photon 
of frequency 2ω. The SHG process is governed by an induced nonlinear polarization at 
2ω, P(2ω), generated when the input photons, ω, spatially and temporally overlap at a 
surface. P(2ω), is given as:    
2.1 General Principles of SHG 
    P(2ω) = χijk
(2)Ej(ω)Ek(ω) ,        (2.1) 
where χijk
(2) is a third rank tensor which describes the macroscopic response of the system 




    
 
and input fields (j,k) which can assume any of the three Cartesian coordinates (x,y,z). As 
a result, χijk
(2) is composed of 27 elements, but it is reduced to 18 elements since Ej(ω) and 






































 .               (2.2) 
 The second-order susceptibility, χijk
(2), is dependent on the symmetry of the system. 
Specifically, in the presence of inversion symmetry, i.e., bulk solution or isotropic media, 
the susceptibility tensor χijk
(2) vanishes under the electric-dipole approximation, and thus 
the SHG process is disallowed. However, inversion symmetry is broken at the interface 
between two isotropic media. The interface between the two isotropic media possesses 
C∞v symmetry as it is symmetric about the surface normal. This results in three nonzero 
independent χijk
(2)  tensor elements,  χzzz , χzii  and χizi  (i = x or y). The symmetry of the 
surface further reduces to C∞ when a chiral molecule present at the surface which gives 
rise for an additional nonzero χijk
(2)
 tensor element, χxyz . These symmetry constraints on 




    
 
 Taking into account the non-vanishing tensor elements, the components of the 
induced polarization in the Cartesian coordinate system (x,y,z) of the achiral surface can 
be written as: 
 Px(2ω) = χxzxEx1(ω)Ez2(ω) + χxzxEz1(ω)Ex2(ω) ,                          (2.3a) 
 Py(2ω) = χxzxEy1(ω)Ez2(ω) + χxzxEz1(ω)Ey2(ω) ,                       (2.3b) 
 Pz(2ω) = χzxx �Ex1(ω)Ex2(ω) + Ey1(ω)Ey2(ω)�+ χzzzEz1(ω)Ez1(ω) ,             (2.3c) 
where Ex, Ey and Ez are the applied electric field vectors in the Cartesian coordinate 
system (x,y,z) for each of the input beams (1 and 2). These electric field vectors in the 
Cartesian coordinate system can be converted to the interfacial coordinate system, shown 
in Figure 2.1, through the following transformations:  
    Ex(ω) = E fxcos(θ)cos(γ) ,                   (2.4a) 
     Ey(ω) = E fysin(γ) ,                  (2.4b) 
    Ez(ω) = E fzsin(θ)cos(γ) ,      (2.4c) 
where E is the amplitude of the applied electric field, which is equal to the square-root of 
the intensity of the input beam I, f is the transmitted linear Fresnel coefficient as the 
transmitted electric field components propagate through the interface. θ is the incident  
angle with respect to the surface normal and γ is the polarization angle relative to the 
plane of the incidence. The polarization angle of the input beam is defined as γ  = 0° or 












Figure 2.1 Schematic of the Cartesian and interfacial coordinate systems. The plane of 
incidence is the xz plane and the surface normal lies along the z-axis. θ is the angle of 
incidence relative to the surface normal and γ is the polarization with respect to the plane 






    
 
coordinate system is defined so that the plane of the incidence lies in the xz plane and the 
surface normal is along the z-axis as shown in Figure 2.1. 
 The expressions for the transmitted linear Fresnel coefficients f in the interfacial 
coordinate system are: 
 










  ,                (2.5a) 
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ω - θTω)  ,                 (2.5c) 
where θI is the incident angle of the fundamental beam and θT is the angle of the 
transmitted beam (Figure 2.1).  
 For a co-propagating geometry where the two incident beams originate from the 
same direction, the induced polarization can then be rewritten as: 
 Px(2ω)= 2√I sinθ cosθ cos2γ fx fz χxzx ,                        (2.6a) 
  Py(2ω)=2√I sinθ sinγ cosγ fy fz χxzx ,                                       (2.6b) 
 Pz(2ω)=√I �( cos2𝜃 cos2γ  fx fx + sin2γ fy fy)χzxx+  sin2𝜃 cos2γ fz fz χzzz� .          (2.6c) 
 The SHG intensities polarized parallel (p) and perpendicular (s) to the plane of 
incidence can be expressed in terms of the induced polarization and a nonlinear Fresnel 




    
 
    Ip = �f̃xPx(2ω) + f�zPz(2ω)�2 ,                  (2.7a) 
    Is = �f̃yPy(2ω)�2 .                  (2.7b) 
The nonlinear Fresnel coefficient f̃  describes the refraction of the SFG output beam 
associated with the induced polarization P(ω3) into the reflection and transmission 
media.2 The expressions for f̃ derived by Bloembergen and Pershan2 and modified by 
Dick et al.3 for a nonlinear wave propagating in a thin nonlinear material between two 
linear media, are given by:  
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where f̃  R and f̃  T are the reflected and transmitted nonlinear Fresnel coefficients, 





    
 
and θT 
 2ω are the reflected and transmitted angles of the sum frequency beam, respectively. 
nR2ω and nT2ω are the refractive indices for the SHG beam in the reflected and transmitted 
media, and nM2ω is the refractive index of the SHG in the nonlinear medium. The presence 
of nM in the nonlinear Fresnel coefficient f̃z, which is a multiplicative factor of Pz(2ω) in 
the expression for Ip (equation 2.7a), can be eliminated by introducing an effective  χ(2)     
( χ eff ) as described by Dick et al.3 The corresponding tensor elements χzzz  and 
χzxx appeared in Pz(ω3) can then be expressed in terms of χ eff according to: 
   χzzz
 eff = d χzzz
(nM
ω3)
2 ; and χzxx
 eff = d χzxx
(nM
ω3)
2  .                 (2.10) 
It should be noted that because nM is not present in f̃x and f̃y,  the 
corresponding χxzx element can simply be rewritten as: 
    χxzx
 eff = d χxzx .                           (2.11) 
The expressions for the nonlinear Fresnel coefficient f̃ in equations 2.8a-c and 2.9a-c no 
longer contain the refractive index, nM, and thickness, d, of the nonlinear medium as these 
two parameters are accounted for in the effective χ eff.  
 It has been shown previously by Kriech and Conboy that a counter-propagating 
geometry where the two incident beams originate from opposite directions (Figure 2.2) 
results in SHG emission along the surface normal, or the z-axis.20 Relative to the 
conventional co-propagating geometry where both input beams approach from the same 
direction (Figure 2.1), counter-propagating geometry allows for a significant separation 












Figure 2.2 Schematic of a counter-propagating SHG. Two fundamental beams at the 
same frequency ω approach the silica/water interface from opposite directions with the 






    
 
propagating geometry, the incident beam approaches the surface under total internal 
reflection and the reflected beam is steered back upon itself. This results in the two 
identical beams arriving at the surface from opposite directions. The x component of the 
electric field vector of the second input beam has the opposite sign of the first input beam 
while the y and z components are unchanged. Therefore, the induced nonlinear 
polarization in x direction, Px(2ω) , becomes zero as Ex1(ω) = - Ex2(ω)  (see equation 
2.3a). Additionally, the induced nonlinear polarization Pz(2ω) in the z direction vanishes 
since the SHG output is emitted along the z-axis. The induced polarization P(2ω) now 
only has one nonzero component propagating in y direction, which is given by: 
    Py(2ω) = I sinθI sinγ cosγ fy fz χxzx K  ,    (2.12) 
where K is the correction for differences of the linear Fresnel coefficients for s- and p- 
polarized inputs (fs
  r and fp
  r ) upon reflection as described by Kriech and Conboy:20  
     K =  fs
  r -  fp  r .                  (2.13) 
The expressions for the linear Fresnel coefficients fs
  r and  fp
  r are given as: 
    fs
  r = 
cosθI  - ��nT nR� �2 - sin2θI
cosθI  + ��
nT nR� �
2 - sin2θI  ,           (2.14a) 
    fp 
  r=
 -�nT nR� �2 cosθI  + ��nT nR� �2 - sin2θI
�nT nR� �
2
 cosθI  + ��
nT nR� �
2 - sin2θI   .              (2.14b) 




    
 
     Iy(2ω) = �Py(2ω) f�y�
2
 ,                         (2.15) 
where the nonlinear Fresnel coefficient f̃y is determined using equation 2.8b for reflection 
or equation 2.9b for transmission. For the counter-propagating geometry used here, f̃y is 
reduced to: 
     f̃y
  R = f̃y
  T = 8 π ω
c nR
2ω  .                 (2.16) 
 Substitution of equation 2.12 for the Py(2ω) and equation 2.16 for the f̃y  into 
equation 2.15, the reflected and transmitted SHG intensity in y polarization can be 
rewritten as: 
  Iy R(2ω) = Iy T(2ω) = 64 π2 (sinθi)2 (sinγ)2 (cosγ)2 fy 2 fz 2 χxzx 2  K2
c2 (nR
2ω)
2  .                (2.17) 
 As previously described, SHG is allowed at an interface between two isotropic 
media but prohibited in centrosymmetric bulk material due to the symmetry constraint of  χ(2) . As a result, χ(2) , and subsequently the SHG intensity, are sensitive only to the 
molecules present at the interface making SHG a highly surface specific process. χ(2) is 
comprised of two components: a nonresonant portion, χNR 
(2)  and a resonant portion, χR(2): 
     χ(2) = χNR
(2)  + χR
(2) .                 (2.18) 
The resonant portion χR
(2)can be given as: 
   χR
(2) = N ∑
�a�μi�c��a�μj�b��b�μk�c�
�2hω - Eca - iΓca��hω - Eab - iΓab�a,b,c




    
 
where N is the surface density of molecules, h is Planck’s constant, µ is the Cartesian 
coordinate dipole operator, Γ represents the linewidth of the transition, and a, b and c 
represent the initial, intermediate and final states, respectively (see Figure 2.3).1  
 Examination of equation 2.19 shows that the denominator will approach zero 
when the fundamental frequency, ω, or the SHG frequency, 2ω, approaches the 
frequency of an allowed dipole moment transitions at surfaces/interfaces. This causes an 
increase in the overall χ(2)  accompanied by an enhancement in the SFG intensity 
according to the relationship described in equations 2.17. This resonant enhancement in 
SHG has been utilized to investigate protein adsorption at a solid/liquid interface,21,22 as 
well as peptide23,24 and chiral molecule20,23 association to a lipid bilayer.  
 In this chapter, the general principles of the nonlinear optical spectroscopy SHG 
were discussed. Due to the symmetry constraints, SHG is only allowed at surfaces or 
interfaces making the technique extremely surface sensitive. Additionally, the SHG 
intensity can be significantly enhanced when the fundamental or the nonlinear field's 
frequency is in resonance with electronic transitions of molecules presenting at 
surfaces/interfaces. This feature can be used as a sensitive and intrinsic probe to detect 
biomolecular interactions at a surface. The application of SHG in studying protein-ligand 
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CHAPTER 3 
INVESTIGATION OF BIOTIN BOUND PROTEIN-BIOTINYLATED LIPID 
INTERACTIONS WITH SECOND HARMONIC GENERATION  
3.1 Introduction 
 As previously discussed in Chapter 2, the symmetry constraint in second 
harmonic generation (SHG) makes it a surface specific technique. The susceptibility 
tensor and subsequently the SHG intensity can be significantly increased when the 
fundamental or SHG frequency is in resonance with an electronic transition of a molecule 
of interest at a surface. This feature of SHG can be exploited as an intrinsic and sensitive 
probe to detect the presence of the molecule adsorbed at the surface. These characteristics 
make SHG an extremely attractive and sensitive technique for detecting biomolecular 
interactions at surfaces/interfaces. In this chapter, the application of SHG for studying 
protein binding to ligand immobilized at a lipid bilayer surface without using any 
extrinsic label is described.  
Biotin bound protein complexes have been used in a wide variety of bioanalytical 
applications, including monitoring conformation changes in biomolecules,1,2 fabrication 
of biochip sensors,3-11 immunoassays,12,13 and targeted drug delivery and screening.14 In 
these applications, the protein-biotin complex is commonly used to tether biomolecules to 
a surface1,2,15,16 or used as a linker to capture biomolecules3-14,17 by taking advantage of 
the high affinity, specificity and stability of biotin bound proteins such as avidin,10-12,16 
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streptavidin,1-3,13-15 neutravidin,4-6 and anti-biotin antibody.7-9 Avidin is a 66 kDa tetramer 
consisting of 4 identical subunits, each of which has one binding site for biotin. It has an 
extremely high binding affinity, Ka ∼ 1015 M-1 to free biotin in solution,18 and forms a 
stable complex with biotin over a wide range of temperatures and pHs.19 One major 
drawback to using avidin is the high degree of nonspecific adsorption caused by its basic 
isoelectric point (pI ~ 10).19 At physiological pH, positively charged avidin can bind 
nonspecifically to negatively charged surfaces such as cell membranes19 or silica 
substrates.20 Another feature that contributes to avidin’s high nonspecific adsorption is its 
carbohydrate groups which contain four mannose residues and three N-acetyl-
glucosamine residues per subunit.21 If the avidin-biotin complex is being used to capture 
a carbohydrate-binding molecule it can also bind specifically to the carbohydrate groups 
on avidin, limiting its use in bioassays. Both streptavidin and neutrAvidin, analogs of 
avidin, which also have a high affinity and specificity towards biotin22,23 have been used 
as an alternative to avidin.3-6 Streptavidin, which has a similar functional domain to 
avidin (~ 33% identical residues),22 is a nonglycosylated protein expressed from 
Streptomyces avidinii bacteria with a slightly acidic pI of about 5-6.19 NeutrAvidinTM is a 
commercially available deglycosylated form of avidin with a pI of 6.3.24 The lower pIs 
and absence of the sugar groups in streptavidin and neutrAvidinTM are intended to lower 
the nonspecific binding relative to avidin without significantly affecting the affinity for 
biotin. As such streptavidin and neutrAvidinTM are commonly used in biosensing 
applications as an alternative to avidin as a way to reduce nonspecific binding to the 
sensor surfaces. Anti-biotin antibody, a 150 kDa immunoglobulin (IgG) protein that is 
generated by the immune cell in response to the antigen biotin, has also been used as an 
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alternative linker to capture biomolecules on biosensor surfaces.7-9 Similar to streptavidin 
and neutrAvidinTM, anti-biotin antibody has a high binding affinity for biotin (~ 108 M-
1).25 Additionally, use of the anti-biotin antibody-biotin complex has been shown to 
increase biomolecular capture in biosensing applications as compared to the streptavidin-
biotin complex.7,9 Surprisingly, little work to date has compared the specific and 
nonspecific affinities of avidin, streptavidin, neutrAvidinTM, and anti-biotin antibody to 
biotin at surfaces despite the use of these proteins in a broad range of biosensing 
applications. In this work, the binding affinities of these biotin-binding proteins to 
biotinylated lipid bilayers were measured as well as the energetics of the binding process 
and the nonspecific adsorption of all four proteins were specifically addressed.  
 Biosensing applications have employed the use of protein-biotin complexes to a 
various types of surfaces including functionalized gold surfaces,3-5,13 polymer films,12 
glass,1,26 silver nanoprisms,7 as well as planar supported lipid bilayers (PSLBs) or 
liposomes.15,27 Planar supported lipid bilayers were chosen as a platform for the protein 
binding assays in this study due to the ease of preparation as there is no need for chemical 
modification of the surface. Additionally, PSLBs allow the ligand density to be more 
precisely controlled,28 providing better reproducibility for a comparison between 
experiments.  
The binding affinity between protein-ligand pairs at surfaces is known to be 
affected by the surface density of the ligand.29-31 Zhao and coworkers have shown that 
once the biotin density is high enough to bind a monolayer of avidin any additional biotin 
sterically hinders further avidin binding.30 This study also showed that doubly bound 
avidin-biotin complex (two biotin molecules for every one avidin molecule) is more 
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stable than the singly bound complex.30 This suggests that the optimal biotin density 
would be one that allows a monolayer of avidin to bind bivalently. In this study, the 
appropriate biotin density to form a doubly bound complex monolayer of the protein can 
be calculated using the area for avidin, 3025 Å2 (55 Å × 55 Å),19 and the areas for a lipid 
molecule and biotinylated lipid, 70 Å.32 For a monolayer of avidin (3.31 × 1012 
molecule/cm2) to bivalently bind to biotin, the biotin density must be twice as large; 
therefore, the density of the biotinylated lipid in the lipid bilayer should be about 4.6 mol 
% [(2 × 3.31 × 1012 biotinylated lipid molecule/cm2)/(1.43 × 1014 lipid molecule/cm2) × 
100%]. Previous studies that investigated biotin binding to neutrAvidinTM and 
streptavidin in PSLBs have also shown that protein binding increases with biotin density 
up to 4 mol % and then saturates.33,34 At this biotin density, two biotin molecules 
effectively bind to every one protein to form a doubly protein-biotin complex monolayer 
on the lipid bilayer surface. When the biotin density is lower than 4 mol % (less than a 
monolayer coverage) fewer protein ligand complexes are formed but above 4 mol % 
steric hindrance from neighboring avidin molecules decreases binding. In order to 
provide useful information for bioanalytical applications, which aim to maximize the 
number of captured biomolecules, the optimal biotin density of 4 mol % (a monolayer 
coverage of bivalently bound protein) was used in the current study.  
Several surface specific techniques have been utilized in studying protein-ligand 
interactions. Total internal reflection fluorescence (TIRF) is commonly used to detect 
protein-ligand interaction where the protein of interest is detected via a fluorescent 
probe.23,29,35,36  Although fluorescence possesses an extremely high sensitivity, the 
technique however has its own disadvantages. The labeling of the protein with a foreign 
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fluorescent molecule can change the protein structure and/or charge and consequently 
alter its binding properties.37 To circumvent these issues, label-free techniques such as 
surface plasmon resonance (SPR) and quartz crystal microbalance (QCM) have recently 
drawn great attention. SPR38-40 and QCM20,27,41 have been used to detect protein-ligand 
interactions by measuring the mass change upon the binding event. Despite the fact that 
SPR and QCM offer the advantage of label-free detection, these mass based techniques 
lack the chemical sensitivity of spectroscopic methods.  
In this chapter, SHG was employed as a label-free alternate to investigate the 
interactions between biotin and the four biotin-bound proteins, avidin, streptavidin, 
neutrAvidinTM and anti-biotin antibody. SHG has also been previously used to monitor 
protein adsorption at a solid/liquid interface42,43 and association of biomolecules to a lipid 
monolayer or bilayer.44-48 SHG provides the surface selectivity and high sensitivity 




 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-(Cap biotinyl) (sodium salt) (biotin-cap-DOPE) were obtained 
from Avanti Polar Lipids and used as received. NeutrAvidinTM was purchased from 
Pierce, avidin and streptavidin from Streptomyces avidinii, IgG from rabbit serum and 
anti-biotin antibody produced in goat were obtained from Sigma-Aldrich. All water used 
in the experiments was obtained from a NanopureTM Infinity Ultrapure water system with 
a minimum resistivity of 18.2 MΩ-cm.  Phosphate buffered saline (PBS) was made from 
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50 mM Na2HPO4∙7H20 and 100 mM NaCl in water and adjusted to a pH of 7.4 using 
NaOH. The proteins were dissolved in PBS pH 7.4 to the desired working concentrations. 
The substrates used for the preparation of the PSLBs were custom manufactured full 
spectrum grade (IR/UV) fused silica prisms (Almaz Optics). The prisms were cleaned by 
immersion in a solution of 70% sulfuric acid and 30% hydrogen peroxide overnight. Prior 
to use, the prisms were rinsed thoroughly with water and cleaned with Ar plasma 
(Harrick Scientific Plasma Cleaner/Sterilizer, Ossining, NY) for 3 minutes.   
3.2.2 Small Unilamellar Vesicle (SUV) Preparation 
  All lipids were dissolved in chloroform then evaporated under a gentle stream of 
N2(g) and vacuum dried over night to remove residual solvents. The SUV solutions were 
formed by resuspending the dried lipids in PBS to a concentration of 1 mg/mL by 
vortexing followed by bath sonication for 10 - 30 minutes until the solutions become 
clear.  
 The prism used as PSLB substrates was mounted in a custom built flowcell 
(volume of 0.4 mL). PSLBs were formed on the silica prism by vesicle fusion, which 
involved incubating the surface with the SUV solution for 20 minutes at room 
temperature. The flowcell was then flushed with PBS to remove any free lipid solution.    
3.2.3 Ligand-Protein Binding Assay 
 PSLBs of DOPC containing 4 mol % biotin-cap-DOPE for avidin, neutrAvidinTM, 
streptavidin and anti-biotin antibody binding were created on the prism surface by vesicle 
fusion as described above. To reduce nonspecific adsorption of the proteins, the PSLBs in 
these experiments were incubated in 1mg/mL monoclonal IgG from rabbit serum in PBS 
pH 7.4 for 30 minutes to block any defects that might exist on the lipid surfaces, except 
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for the anti-biotin antibody experiments. The PSLBs were then rinsed thoroughly with 
PBS to remove any free IgG remaining in solution.  
 Increasing concentrations of the protein solutions, from low to high, were injected 
into the flowcell. At each protein concentration, the SHG intensity was recorded at a 30- 
minute interval until a steady-state response was achieved. The SHG intensity collected 
with time allowed kinetic measurement to be determined. Generally, low concentrations 
of the proteins required up to 4 hours to reach equilibrium. During this period, fresh 
protein solution was injected every 30 minutes to account for the bulk depletion caused 
by surface adsorption of the proteins. It is important to note that protein dilutions were 
freshly prepared prior to each injection to further prevent the proteins from 
nonspecifically adsorbing to the vials and syringes. Thermodynamic measurements were 
made using the SHG intensity measured at equilibrium at each protein concentration. 
3.2.4 SHG Measurements 
  Counter-propagating SHG was employed in this study. A collimated 532 nm laser 
beam (2nd harmonic output of a Nd:YAG laser, Continuum, Surelite I, 10 Hz) with a 
mixed polarization state (equal amounts of s and p polarized components) was directed at 
the prism/water interface at an  incident angle of 67° under total internal reflection. The 
incident laser beam with an intensity of 14 mJ/pulse and a diameter of 3 mm was used. 
The reflected beam was steered back to overlap spatially and temporally with the incident 
beam, generating SHG at 266 nm. A schematic representing the optical rearrangement is 
shown in Figure 3.1. Optical filters were used to remove any scattered visible light before 










Figure 3.1 SHG cell showing the geometric arrangement of the fundamental and SHG 
beams. Also shown are representation of the polarization state of the incident and output 
fields denoted as the angle γ with respect to the propagation direction (k) and the lipid 




    
 
 As described in Chapter 2, the SHG intensity is proportional to the second-order 
susceptibility tensor, χijk(2) which has a nonresonant χNR(2)  and resonant χR(2) contribution. An 
enhancement in χR
(2) , and subsequently the SHG signal, will be observed when the 
incident, ω, or SHG, 2ω, frequency is resonant with an electronic transition of a molecule 
at the interface. As seen in the extinction coefficient spectra of the  proteins in Figure 3.2, 
the SHG wavelength at 266 nm is in resonance with the π→π* transitions of the 
tryptophan and tyrosine's aromatic rings of the proteins,49 which results in the 
enhancement of the SHG signal when the protein is present at the lipid membrane 
surface. Although the electric-quadrupole response from the bulk medium can contribute 
to the overall SHG signal,33,34 its contribution can be neglected if the SHG frequency is in 
resonance with the electric-dipole allowed transition of molecules residing at the 
interface.50 As the SHG frequency used in this study is in resonant with the π→π* 
transitions of the proteins adsorbed to the surface, the measured SHG intensity is 
predominantly dipolar in nature with little to no detectable contribution from the 
quadrupolar response expected.  
 In equation 2.33 in Chapter 2, the nonresonant susceptibility χNR
(2)   can be assumed 
to be real due to lack of any electronic resonances from the lipids, water, or silica in the 
spectral region of interest while the resonant susceptibility χR
(2)  is a complex number 
owing to the resonances with the electronic transitions in the proteins. For simplification, 
χNR
(2)  and χR(2)can be expressed as: 
    χNR











Figure 3.2 Extinction coefficient spectra of avidin (solid), neutrAvidinTM (long dash), 





    
 
where A represents the nonresonant response from the background, and B and C denote 
the real and imaginary components of χR
(2), respectively. The SHG intensity in equation 2 
can then be expressed as: 
  ISHG ∝ �χ(2)�2∝ |A + N(B + iC)|2 ∝ (A + NB)2 + (NC)2                       (3.2) 
Assuming the surface adsorption of protein follows the Langmuir model, the surface 
density N in equation 3.2 is given by: 
     N = NmaxKo[𝑃]
1 + Ko[𝑃]  ,                     (3.3) 
where Nmax is the maximum surface density at saturation, Ko is the equilibrium 
association constant and [P] is the bulk protein concentration. Substitution of equation 
3.3 into equation 3.2 gives: 
   ISHG ∝ �χ(2)�2 ∝ �A + B NmaxKo[P]1 + Ko[P] �2 + �C NmaxKo[P]1+Ko[P] �2                                                   ∝ A2 + 2AB NmaxKo[P]
1 + Ko[P]  + �B2 + C2� �NmaxKo[P]1 + Ko[P] �2 .                 (3.4)    
The SHG intensity due to the nonresonant background in the absence of protein 
adsorption is given by: 
     ISHG
background ∝ A2 .                    (3.5) 
Subtracting the background contribution (3.5) from the measured SHG intensity (3.4) 
gives the SHG intensity rising solely from protein adsorption, which can be expressed as: 
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ISHG - ISHGbackground ∝ 2�ISHGbackground B �ISHGMax  Ko[P]1 + Ko[P]  + �B2 + C2���ISHGMax  Ko[P]1 + Ko[P] �2,               (3.6) 
 where �ISHGMax  is the square-root of the maximum SHG intensity at surface saturation. 
�ISHG
background  = A if it is assumed that the real nonresonant response (A) from the 
background is positive.  
 For avidin, a previous study has shown that protein-protein interaction can 
modulate the energetic of protein association to a biotinylated surface.29 When 
interactions between proteins are involved, a cooperative binding model, previously 
described by Zhao et al.,29 can be used to fit the adsorption data: 




Nmax� �Ko[P]  ,                                     (3.7) 
where ω = η4 by assuming the distribution of the biotin-bound proteins follows a square 
lattice and η is the cooperativity coefficient which characterizes the protein-protein 
interactions between neighboring protein molecules on the surface.29 Ko in this equation 
is the intrinsic binding affinity of the protein to the ligand barring any protein-protein 
interactions.29 When η  > 1, the binding of a protein to a ligand exhibits a positive 
cooperativity, demonstrating that the protein-protein interaction enhances the ligand-
protein binding. When η < 1, the protein-protein interaction reduces the ligand-protein 
binding resulting in a negatively cooperative ligand - protein binding. The cooperativity 
model becomes the Langmuir model when η  = 1. 
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The SHG intensity in terms of the cooperativity adsorption model is obtained by 
substituting equation 3.7 into equation 3.2: 


















































.            (3.8) 
3.2.5 Data Normalization 
 To allow a direct comparison of the SHG response from the specific and 
nonspecific binding of the proteins, the SHG intensities were normalized with respect to 
each other. The normalization was performed by measuring the SHG response from 10 
mM KOH solution which was injected into the flowcell after each experiment. The 
measured SHG intensities from the KOH solution were then used to normalize the SHG 
intensities from the specific and nonspecific protein binding experiments. The KOH 
solution was used as a reference point as it provides a constant solution composition and 
pH by which the SHG intensity can be normalized, allowing the comparison between the 
SHG intensities from the specific and nonspecific binding of the proteins to be made. 
3.3 Results and Discussion 
3.3.1 Binding of Avidin, Streptavidin and NeutrAvidinTM to                                                
a Biotinylated DOPC Bilayer 
 The binding isotherms for avidin, neutrAvidinTM and streptavidin are shown in 
Figures 3.3, 3.4 and 3.5, respectively. The SHG intensities increase with increasing 
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Figure 3.3 Corrected SHG intensity vs. bulk protein concentration for avidin binding to 
DOPC bilayers containing 4 mol % biotin-cap-DOPE (filled circles) and 0 mol % biotin-
cap-DOPE (open circles). The solid line is the fit to the cooperativity binding model. The 
error bars represent the standard deviation from three independent experiments. 
39 
 












Figure 3.4 Corrected SHG intensity vs. bulk protein concentration for streptavidin 
binding to DOPC bilayers containing 4 mol % biotin-cap-DOPE (filled circles) and 0 mol 
% biotin-cap-DOPE (open circles). The solid line is the fit to the cooperativity binding 
















Figure 3.5 Normalized SHG intensity vs. bulk protein concentration for neutrAvidinTM 
binding to DOPC bilayers containing 4 mol % biotin-cap-DOPE (filled circles) and 0 mol 
% biotin-cap-DOPE (open circles). The solid line is the fit to the cooperativity binding 




    
 
protein concentration until saturation coverage is achieved at concentration greater than 
100 nM. The Langmuir and cooperativity models were both used to fit the binding 
isotherms and the f-test was then performed to determine the best fit for the data.  
The Langmuir model (equation 3.6) was used to fit the binding data with the fitting 
parameters B, C, �ISHG Max and Ko by performing a nonlinear least-square regression. The 
cross term in equation 8 is the product of the nonresonant, A, and real component, B, of 
the resonant susceptibility tensor which describes the interference between the 
background and protein adsorption responses. Assuming the nonresonant term A is real 
and positive, the measured SHG intensity can increase or decrease due to  constructive (A 
and B have the same sign) or destructive (A and B have different signs) interference. In 
this work as seen in Figures 3.3-3.5, no initial decrease in the SHG intensity was 
observed at low protein concentrations where the contribution of the resonant term is 
presumably not much greater than the nonresonant contribution, suggesting there is 
constructive interference between the background and protein responses. This indicates 
the cross term (2AB) will be positive such that A and B have the same sign. Additionally, 
the results from the nonlinear regression indicate that the magnitude of B is 
approximately eight orders of magnitude smaller than magnitude of the imaginary portion 
of the resonant susceptibility tensor (C). Since the contribution from the cross term 
�2B�ISHG
 background� in equation 8 is much smaller compared to the resonant contribution 
term (B2 + C2), it can be neglected. The resonant contribution term (B2 + C2), which is 
related to the surface density (see equation 2.19 in Chapter 2), serves as a scaling factor, 
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and can then be pooled into �ISHG Max . Using these simplifications, the final Langmuir 
equation used to fit the adsorption data in this study is: 
    ISHG ∝ �
�ISHG
 Max Ko[P]
1 + Ko[P] �
2
 .                 (3.10) 
The cooperativity model (equation 3.8) was also used to fit the binding data with 
the fitting parameters B, C, Nmax, Ko and ω. The fitting results also showed that 
�2B�ISHG
 background� is seven orders of magnitude lower than (B2 + C2), and thus the 
contribution of the cross term in equation 3.8 is negligible. Therefore, the final form of 
the cooperativity model used to fit the data has the form: 
































 .                    (3.11) 
 The equations 3.10 (Langmuir model) and 3.11 (cooperativity model) were then 
used to fit the adsorption data of avidin and its analogs, streptavidin and neutrAvidinTM 
shown in Figures 3.3-3.5. It was found that the cooperativity model (equation 3.11) 
statistically fit the data best and the results from a nonlinear least-square regression of the 
data are given in Table 3.1.  
 The results summarized in Table 3.1 show that the binding affinities, Ko, of 
avidin, streptavidin, neutrAvidinTM to a biotinylated DOPC bilayer, 8.2 ± 2.4 × 107 M-1, 
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Table 3.1 Measured intrinsic binding affinity and cooperativity coefficient for 
 avidin, streptavidin, and neutrAvidinTM. 
Protein Ko × 107 (M-1) η (a.u.) 
Avidin 8.2 ± 2.4 1.2 ± 0.2 
Streptavidin 4.3 ± 0.9 1.8 ± 0.2 
NeutrAvidinTM 2.6 ± 0.01 1.9 ± 0.01 
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4.3 ± 0.9 × 107 M-1 and 2.6 ± 0.01 × 107 M-1, respectively, are quite comparable. The 
binding affinity of avidin to biotin obtained in this study is in good agreement with the 
value of 2.14 ± 0.20 × 107 M-1 previously reported by Zhao et al. for fluorescently 
labeled avidin binding to a 0.63 mol % biotinylated lipid (a ligand density high enough to 
bind to a monolayer of avidin) incorporated into an arachidic acid monolayer.29 For 
streptavidin, the biotin-binding affinity obtained here is slightly higher than the value of 
7.3 ± 0.2 × 106 M-1 reported by Tang and coworkers for streptavidin binding a biotin 
monolayer functionalized on a SPR gold chip surface.40 The difference in the binding 
affinity of streptavidin between the two studies can be related to the difference in the 
surface density of biotin used. It is likely that the high density of biotin used in the SPR 
study creates steric hindrance which lowers the accessibility of an individual biotin to the 
protein binding sites, resulting in a lower binding affinity. For neutrAvidinTM binding to 
the protein binding sites, resulting in a lower binding affinity. For neutrAvidinTM binding 
to biotin, the Ko of 1.6 ± 1.1 × 107 M-1 measured in this study is about 4.5 orders of 
magnitude smaller than an affinity of 5.5 ± 0.2 × 1011 M-1 reported by Wayment and 
Harris using single-molecule fluorescence.23 In order to compare the result of Wayment 
and Harris' study with the one of the current study, we performed a similar analysis of the 
kinetics of protein binding which is presented in the following section. It was shown that 
the slower adsorption and desorption rates of biotin-neutrAvidinTM measured in this study 
lead to the lower binding affinity.  
 As previously mentioned, the cooperativity binding model was statistically the 
best fit to the data obtained in the present work. This indicates that protein-protein 
interactions are involved in the biotin-protein binding. The value of the cooperativity 
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coefficient η obtained from the fit is shown in Table 3.1. A value of η greater than unity 
was obtained for avidin, streptavidin and neutrAvidinTM, illustrating that all the proteins 
exhibit positive cooperative binding behavior. This suggests that the binding of the 
proteins to biotin is increased due to protein-protein interactions. Similar cooperative 
binding behavior has been previously observed for avidin to a monolayer of arachidic 
acid containing biotinylated lipid.29 The cooperative binding of avidin was only observed 
if the biotin density was adequately high to bind to a monolayer of avidin so that the 
distance between the biotin molecules is close enough for the adjacent biotin bound 
avidin to interact with an incoming avidin.29 Additionally, biotin needs to be placed 
above the lipid surface, i.e., by the use of a spacer between biotin and the lipid head 
group, to provide more accessibility for avidin binding.29 The use of a biotin density high 
enough to form a monolayer of the proteins (~ 4 mol % biotin) and the spacer between 
biotin and the lipid head group (biotin-cap-DOPE) in the present study allows for protein-
protein interactions to occur.  
 Interestingly, in this study avidin was found to have a smaller η (1.2 ± 0.2) as 
compared to streptavidin and neutrAvidinTM (1.8 ± 0.2 and 1.9 ± 0.01) indicating that 
avidin exhibits less positive cooperative binding. The lower cooperativity observed for 
avidin could be related to the high pI (~ 10) of the protein. At the neutral pH used here, 
avidin is positively charged, and thus the electrostatic repulsion between the charged 
avidin proteins could repel the proteins from each other resulting in a reduction in avidin-
avidin interactions. On the other hand, streptavidin and neutrAvidinTM have a pI close to 
7. Therefore, electrostatic interaction between streptavidin and streptavidin or 
neutrAvidinTM and neutrAvidinTM is less pronounced as compared to that of avidin-avidin 
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interactions, resulting in a higher cooperativity coefficient obtained for streptavidin and 
neutrAvidinTM. 
  The level of cooperative binding observed in avidin, streptavidin and 
neutrAvidinTM can also be evaluated in terms of the binding free energy. Without any 
contributions from protein-protein interaction, the free energy of protein-biotin binding, 
∆Go, can be calculated from the intrinsic binding affinity Ko: 
     ∆Go = - RT lnKo .                  (3.12) 
The calculated values of ∆Go for the three proteins are listed in Table 3.2. When the 
protein-protein interaction is not included, ∆Go of avidin binding to biotin (- 45 ± 0.2 
kJ/mol) is slightly higher than that of streptavidin (- 43 ± 0.7 kJ/mol) and neutrAvidinTM 
(- 42 ± 0.5 kJ/mol).  
 The free energy ∆Gη of protein-protein interactions, previously described by Zhao 
et al.,29 can be expressed as: 
     ∆Gη = - 4RT ln(η).                  (3.13) 
Using equation 3.13, ∆Gη was calculated from the binding isotherms in Figures 3.3 - 3.5 
for avidin, streptavidin and neutrAvidinTM and the results are listed in Table 3.2. The 
protein-protein interactions for avidin contribute a free energy (- 1.7 ± 1.4 kJ/mol K) of 
about 3 times less than streptavidin and neutrAvidinTM (- 5.7 ± 1.1 and - 6.3 ± 0.04 
kJ/mol K).  
The total free energy of the protein-biotin binding including the contribution from the 
protein-protein interactions was determined using the following equation: 
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Table 3.2 Calculated intrinsic free energy, free energy due to protein-protein 
 interactions, total free energy, and apparent binding affinity for avidin, 
 streptavidin, and neutrAvidinTM. 
Protein  ∆Go (kJ/mol) ∆Gη (kJ/mol) ∆Gtotal (kJ/mol) Kapp × 107 (M-1) 
Avidin - 45 ± 0.8 - 1.7 ±1.4 - 47 ± 1.7 18 ± 14 
Streptavidin - 44 ± 0.5 - 5.7 ± 1.1 - 49 ± 0.6 44 ± 10 




    
 
     ∆Gtotal = ∆Go + ∆Gη ,                 (3.14) 
the results of which are listed in Table 3.2. The calculated total free energy ∆Gtotal of 
avidin-biotin binding (- 47 ± 1.7 kJ/mol) is now lower than ∆Gtotal of streptavidin (- 49 ± 
0.6 kJ/mol) and neutrAvidinTM (- 49 ± 0.05 kJ/mol) binding to biotin. Accordingly, the 
binding between biotin and streptavidin or biotin and neutrAvidinTM becomes more 
energetically favorable due to the stronger protein-protein interaction as compared to the 
avidin-biotin binding.  
 From ∆Gtotal calculated above, the apparent binding affinity Kapp of the proteins to 
a biotinylated lipid bilayer was calculated and the results are given in Table 3.2. The 
larger calculated values for Kapp as compared to the intrinsic binding affinity Ko reveal 
that the the binding affinity of the proteins toward biotin is enhanced by protein-protein 
interactions. When these protein-protein interactions are taken into account, avidin has 
the lowest biotin-binding affinity of 18 ± 14 × 107 M-1 while streptavidin and 
neutrAvidinTM exhibit stronger binding affinities of 44 ± 10 × 107 M-1 and 33 ± 0.3 × 107 
M-1, respectively. 
3.3.2 Nonspecific Adsorption of Avidin, NeutrAvidinTM and                             
Streptavidin to a DOPC Bilayer 
 The nonspecific adsorption of avidin, streptavidin and neutrAvidinTM to the IgG 
passivated DOPC bilayer without the biotin ligand is shown by the open circles in 
Figures 3.3 - 3.5. The amount of nonspecific adsorption of the proteins can be evaluated 
using the square-root of the SHG intensity,�𝐼𝑆𝐻𝐺, which is directly proportional to the 
surface concentration of the protein. To compare the amount of nonspecific adsorption, 
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the % surface coverage in the absence of biotin at 537.6 nM (above saturation 
concentration) relative to the calculated monolayer coverage of adsorbed protein in the 
presence of biotin was calculated. Surprisingly, neutrAvidinTM has the highest degree of 
nonspecific adsorption (~ 40%) to a pure DOPC bilayer as compared no appreciable 
nonspecific adsorption of avidin and streptavidin. Similar behavior has previously been 
reported for the nonspecific adsorption of neutrAvidinTM to a silica surface where its 
nonspecific adsorption is about three-fold greater than that of avidin.20 The higher degree 
of nonspecific adsorption of neutrAvidinTM is unexpected because the deglycosylation 
and lower pI of neutrAvidinTM are intended to decrease its nonspecific adsorption relative 
to avidin. It is important to mention that although streptavidin is also a nonglycosylated 
protein and has a similar pI to neutrAvidinTM, the degree of nonspecific adsorption of 
streptavidin is much less. Consequently, the removal of the carbohydrate groups and the 
lower pI of neutrAvidinTM cannot account for the greater nonspecific adsorption of the 
protein observed in this study.  
3.3.3 Kinetics of Avidin Binding to a Biotinylated DOPC Bilayer 
In addition to obtaining the binding affinity of the protein to biotin from the 
equilibrium thermodynamics, the binding affinity from kinetic measurements can also be 
determined. The comparison between the binding affinities obtained from the 
thermodynamic and kinetic measurements will indicate whether or not the 
thermodynamic study was made under steady-state equilibrium. The kinetics of protein 
binding to a biotinylated DOPC bilayer can be described by the Langmuir kinetic model51 
where the protein adsorption rate (kon) is first-order with respect to the bulk protein 
concentration Cbulk and fraction of unbound biotin (1-θ), and the protein desorption rate 
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(koff) is first-order with respect to the fraction of protein bound biotin (θ). The rate of 
change in the fraction of protein bound biotin is the difference between the adsorption 
rate and desorption rate as given by: 
    dθ
dt
 = konCbulk�1 - θ� - koffθ .         (3.15) 
θ  is the ratio of the square-root SHG intensity and the square-root of the maximum SHG 
intensity at saturation. The Langmuir kinetic model used here assumes the bulk 
concentration of the protein is unchanged with time. This assumption is valid for the 
current study as the protein concentration was replenished during the adsorption process.  
 Since the SHG intensity and subsequently θ were measured with increasing the 
bulk protein concentration throughout the course of a single experiment, the change in θ  
as function of time at each bulk protein concentration can be plotted separately by setting 
the time t that a new Cbulk was introduced into the system to zero. The corresponding θo at 
t = 0 at each Cbulk is the maximum θ  obtained at the previous bulk protein concentration. 
θ  for avidin binding to a 4 mol % biotinylated DOPC bilayer as a function of time in the 
concentration range from 9.25 nM to 537.6 nM is plotted in Figure 3.6.  
Equation 3.15 was solved with the boundary conditions such that at time t = 0, the 
initial surface coverage fraction is θo, and at time t > 0 the surface coverage fraction is θ . 
These boundary conditions allow the kinetics of protein binding at each bulk protein 
concentration to be evaluated. The solution for equation 3.15 with the above stated 
boundary conditions is: 
 𝜃  = konCbulk
konCbulk + koff �1 - exp�- konCbulk + koff�t� + θoexp�- konCbulk + koff�t ,    (3.16) 
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Figure 3.6 Fraction of surface coverage, θ, vs. time of avidin binding to a 4 mol % 
biotinylated DOPC bilayer at the following bulk avidin concentration:  9.25 nM (circles), 
18.5 nM (squares), 37.0 nM (diamonds), 73.7 nM (upright triangles), 137.7 nM (inverted 
triangles), 273.2 nM (stars), and 537.6 nM (crosses). The lines are the global fit to 
equation 3.16.  
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θo in equation 3.16 is zero for the first and lowest protein concentration. When the next 
protein concentration is added, θo is the maximum fraction of surface coverage at the 
previous protein concentration. 
 Using equation 3.16 to simultaneously fit all adsorption data in Figure 3.6 gives 
the adsorption rate, kon = (9.8 ± 5.3) × 103 M-1 s-1 and the desorption rate, koff  = (6.0 ± 1.8) 
× 10-5 s-1. From the measured kon and koff, the affinity of avidin binding to a 4 mol % 
biotinylated lipid bilayer can be calculated by Ka = kon/koff  = (16 ± 10) × 107 M-1. This 
value is consistent with the Kapp of avidin ((18 ± 14) × 107 M-1) obtained from steady-
state equilibrium thermodynamics measurements presented in the previous section. The 
agreement between the binding affinity obtained from the kinetics and thermodynamics 
indicates that there was sufficient time for each protein concentration to reach 
equilibrium in the thermodynamic measurement.  
 As previously mentioned, there is a large discrepancy between the binding affinity 
measured in this work and Wayment and Harris' one. This discrepancy can be explained 
using the binding kinetics result obtained from the two studies as the same Langmuir 
kinetic model was used to analyze the data. Here the measured kon is about 4.5 orders of 
magnitude slower than that reported by Wayment and Harris ((2.1 ± 0.5) × 108 M-1 s-1).23 
The much slower adsorption rate at a high density of biotin to form a monolayer coverage 
of the protein suggests that the binding affinity of avidin to biotin is much weaker in this 
work. A speculative explanation for this behavior is that the avidin-biotin binding might 
involve two regimes: i) at a very low bulk protein concentration, the protein binds to 
biotin with a very high affinity as observed by Wayment and Harris; and ii) at a higher 
bulk protein concentration, the protein binds to biotin with a lower affinity as seen here. 
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Since a biphasic binding isotherm was not observed in this study, it is possible that the 
protein with the high binding affinity to biotin saturates at very low surface coverage. 
Using a pM range of bulk protein concentration to bind to a very small biotin density to 
form less than 10-6 of a protein monolayer, the high affinity binding regime of the protein 
could be detected as seen by Wayment and Harris. In contrast, with a higher bulk protein 
concentration (~ nM) and a large surface coverage of bound protein, the high affinity 
sites cannot be observed as they do not account for much of the surface density of bound 
protein. This explains the measured lower affinity of the protein binding to biotin in this 
study because the more moderate affinity sites are more prevalent. Additionally, koff  in 
this study is ~ 1.5 orders of magnitude slower than the value measured by Wayment and 
Harris ((3.8 ± 0.5) × 10-4 s-1),18 illustrating the formation of the longer-lived doubly 
biotin-neutrAvidinTM complex in this work. The slower adsorption and desorption rates 
of avidin binding obtained here result in a smaller binding affinity relative to the high 
binding affinity seen in Wayment and Harris' work. 
3.3.4 Binding of Anti-biotin Antibody to a Biotinylated DOPC Bilayer 
 The binding isotherm for anti-biotin antibody binding to a DOPC bilayer 
containing 4 mol % biotin-cap-DOPE is shown in Figure 3.7. The binding of anti-biotin 
was fit using the Langmuir model from equation 3.11. The binding affinity of anti-biotin 
antibody to the biotinylated lipid bilayer of (1.0 ± 4.0) × 108 M-1 measured here is close 
to the value ((2.8 ± 0.8) × 108 M-1) obtained by Jung et al. for fluorescently labeled anti-
biotin antibody binding to 5 mol % biotin-cap-PE incorporated into a lipid bilayer.25  
 A direct comparison between the binding affinities measured in this study for 
anti-biotin antibody, avidin, streptavidin and neutrAvidinTM can be made as they were all  
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Figure 3.7 Normalized SHG intensity vs. bulk protein concentration for anti-biotin 
antibody binding to DOPC bilayers containing 4 mol % biotin-cap-DOPE (filled circles) 
and 0 mol % biotin-cap-DOPE (open circles). The solid line is the fit to the Langmuir 




    
 
determined under similar experimental conditions. The apparent binding affinity of 
avidin, streptavidin and neutrAvidinTM were used in the comparison as it takes account 
into protein-protein interactions involved in the binding of these proteins. Since no 
protein-protein interactions were observed in anti-biotin antibody, thus the apparent 
binding affinity is equal to the intrinsic binding affinity. Interestingly, the binding affinity  
of anti-biotin antibody to a biotinylated lipid bilayer was found to have the same order of 
magnitude (~ 108 M-1) as the apparent binding affinity of avidin, streptavidin and 
neutrAvidinTM. As a result, the free energy of anti-biotin antibody binding to biotin (46 ± 
1.0 kJ/mol) is also close to those of avidin, streptavidin and neutrAvidinTM (see Table 
3.1). 
 Streptavidin and anti-biotin antibody have also been previously found to have the 
same affinity to biotin when biotin is attached to bovine serum albumin (BSA) via a 
caproic acid linker52 even though it is well known that anti-biotin antibody binds to free 
biotin in solution with a much lower affinity than avidin.52,53 This could be explained by 
the higher dependence of avidin's binding affinity on the biotin accessibility, i.e., lower 
accessibility of biotin when it is attached to a macromolecule and higher biotin 
accessibility when it is free in solution. The avidin's binding sites are located in a 
depression near the end of the β-barrels22 which makes it more difficult to bind with 
biotin when biotin is bound to a macromolecule and therefore, lowers the binding affinity 
of avidin.52,54 Unlike the binding sites of avidin, anti-biotin antibody's binding sites are 
located on the end of the Fab segments, not in the depression,55 which makes the binding 
affinity of anti-biotin antibody less dependent on the accessibility of biotin.52 
Furthermore, the Fab segments of the antibody are connected by a hinge that allows the 
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Fab segments to move from about 0° to 180°.56 The flexibility of the Fab segments, 
including the arm rotation, elbow bend and arm wagging,57 allows the antibody to adjust 
the spacing and orientation of its binding sites and thus facilitates the binding of the 
antibody to the ligand.55,56 Therefore, the biotin-binding of anti-biotin antibody is not 
significantly affected by the accessibility of biotin, whereas the lower accessibility of 
biotin in the biotinylated lipid bilayer causes a reduction in the binding affinity of avidin, 
streptavidin and neutrAvidinTM to a biotinylated lipid bilayer. This results in the same 
order of magnitude of the binding affinity for all four proteins to the biotinylated lipid 
bilayer obtained in the present study. 
 Another interesting feature observed here is the nonspecific adsorption of anti-
biotin antibody to a pure DOPC bilayer is negligible as compared to its specific binding 
(see Figure 3.7). It should be noted that no IgG from rabbit serum was used to suppress 
the nonspecific adsorption of anti-biotin antibody in this experiment. Therefore, this 
feature could make the anti-biotin antibody-biotin complex a prominent tether/linker in 
all bioanalytical applications as the time and cost in minimizing the protein's nonspecific 
adsorption can be avoided. 
3.4 Summary 
 The binding of avidin, streptavidin, neutrAvidinTM, and anti-biotin antibody to a 
biotinylated lipid bilayer was investigated using SHG spectroscopy. The binding 
affinities of avidin, streptavidin, neutrAvidinTM and anti-biotin antibody to 4 mol % 
biotin-cap-DOPE incorporated into a DOPC lipid were determined and correlated to the 
values published in the literature, validating the capability of SHG in detection of protein-
ligand interactions without using any extrinsic label. A positive cooperative binding 
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behavior was obtained for avidin and its analogs, streptavidin and neutrAvidinTM, 
demonstrating that protein-protein interactions enhance the binding of the proteins to 
biotin. In fact, the binding of streptavidin and neutrAvidinTM to biotin is more 
energetically favorable than avidin due to the stronger protein-protein interactions. 
Although neutrAvidinTM is designed to lower the nonspecific adsorption, we have found 
that it exhibits the greatest degree of nonspecific adsorption to a DOPC bilayer as 
compared to avidin and streptavidin. Anti-biotin antibody was found to bind to a 
biotinylated lipid bilayer with a similar affinity as avidin, streptavidin and neutrAvidinTM. 
Furthermore, anti-biotin antibody showed negligible nonspecific adsorption to a DOPC 
bilayer without the use of an additional agent to reduce the protein's nonspecific 
adsorption. The study presented in this chapter has demonstrated the utility of SHG as an 
attractive alternative in measuring protein-ligand interactions without the need for 
chemical modification. Furthermore, this study provides a deeper understanding about the 
binding properties of avidin, streptavidin, neutrAvidinTM and anti-biotin antibody to the 
ligand biotin at lipid bilayer surfaces, which can further assist in selecting an appropriate 
tether/linker for biosensing and other bioanalytical applications. 
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CHAPTER 4 
GENERAL PRINCIPLES OF ULTRAVIOLET-VISIBLE SUM-FREQUENCY 
GENERATION 
 Sum-frequency generation (SFG) is a coherent second-order nonlinear optical 
process in which the two input beams at frequencies ω1 and ω2 are combined to generate 
the third beam whose frequency, ω3, is the sum of the input frequencies (ω3 = ω1 + ω2). 
Since a complete theory of SFG has been presented in the literature,1,2 only the general 
principles of SFG will be described in this chapter. Special attention is given to the 
counter-propagating geometry which will be used in the study described in Chapter 5. 
This optical geometry allows for a better separation of the SFG beam from the incident 
beams. The specific case of SFG generated by the combination of ultraviolet and visible 
laser sources will also be discussed.  
 SFG is a more general case of SHG where the frequencies of the two incident 
photons are not the same. SFG is governed by an induced nonlinear polarization at ω3, 
P(ω3), generated when the input photons, ω1 and ω2, spatially and temporally overlap at a 
surface. P(ω3) is given as: 
4.1 General Principles of SFG 
      P(ω3) = χijk
(2) Ej(ω1) Ek(ω2) ,                   (4.1) 
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where χijk
(2) is a third rank tensor which describes the macroscopic response of the system 
to the applied electric fields Ej(ω1) and Ek(ω2). The indices represent the output SFG (i) 
and input fields (j,k) which can assume any of the three Cartesian coordinates (x,y,z). As 
a result, χijk
(2)  is composed of 27 elements, thus the induced polarization can be 

















































 .  
                             (4.2) 
 Similar to SHG, the second order susceptibility, χijk
(2) , is dependent on the 
symmetry of the system. The C∞v symmetry at the interface between the two isotropic 
media allows four unique χijk
(2) tensor elements, χzzz, χzii, χiiz and χizi (i = x or y) to persist.  
 The components of the induced polarization in the Cartesian coordinate system of 
the interface (x,y,z) can be expressed in terms of the nonzero tensor elements: 
 Px(ω3) = χxxz Ex(ω1) Ez(ω2) + χxzx Ez(ω1) Ex(ω2) ,                 (4.3a) 
 Py(ω3) = χyyz Ey(ω1) Ez(ω2) + χyzy Ez(ω1) Ey(ω2) ,                 (4.3b) 
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 Pz(ω3) = χzxx Ex(ω1) Ex(ω2) + χzyy Ey(ω1) Ey(ω2) + χzzz Ez(ω1) Ez(ω2) .     (4.3c) 
 The applied electric field vectors Ex, Ey and Ez in the Cartesian coordinate system 
(x,y,z) can be transformed into the interfacial coordinate system as shown in Chapter 2, 
equations 2.4a-c. The induced polarization in the interfacial coordinate system is then 
given as: 
Px(ω3) =  �I1 �I2�cos γ1 cos γ2�cos θ1 sinθ2 f1x f2z χxxz + sinθ1 cosθ2 f1z f2x χxzx�� ,   (4.4a) 
Py(ω3) = �I1 �I2 �sinθ2 sin γ1 cos γ2 f1y f2z χxxz + sinθ1 cosγ1 sinγ2  f1z f2y χxzx� ,       (4.4b) 
Pz(ω3)= �I1�I2 ��cosθ1cosθ2 cosγ1cosγ2 f1x f2x + sinγ1sinγ2 f1y f2y�  χzxx   + 
                                  sin θ1 sin θ2  cosγ1cosγ2 f1z f2z χzzz � ,                  (4.4c) 
where I1 and I2 the intensities of the input beam 1 and 2, respectively. θ1 and θ2 are the 
incidence angles with respect to the surface normal, γ1 and γ2 are the polarization angles 
relative to the plane of the incidence of the input beam 1 and 2 (see Figure 2.1 in Chapter 
2). The linear Fresnel coefficients fs in the transmitted direction are given in equations 
2.5a-c in Chapter 2.  
 The p and s-polarized SFG intensities can be expressed in terms of the induced 
polarization and a nonlinear Fresnel coefficient f̃ as shown below: 
    Ip = �f̃x Px(ω3) + f̃z Pz(ω3)�2 ,                  (4.5a) 
    Is = �f̃y Py(ω3)�2.       (4.5b) 
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Substitution of equations 4.4a-c into the expressions for p-polarized and s-polarized SFG 
intensities (equations 4.5a-b) yields: 
Ip = I1I2�f̃x�cos γ1 cos γ2�cos θ1sinθ2 f1x f2z χxxz + sinθ1cosθ2 f1z f2x χxzx��  +    
 f̃z �� cosθ1cosθ2cosγ1cosγ2 f1x f2x + sinγ1sinγ2 f1y f2y�  χzxx +  
    sin θ1 sin θ2cosγ1cosγ2 f1z f2z χzzz��
2
 ,                    (4.6a) 
Is = I1I2 �f̃y �sinθ2 sin γ1 cos γ2 f1y f2z χxxz + sinθ1 cosγ1 sinγ2 f1z f2y χxzx��2.     (4.6b) 
 The nonlinear Fresnel coefficients 𝑓, which describe the propagation of the SFG 
beam are given in Chapter 2, equations 2.8a-c, 2.9a-c for both reflection and transmission 
directions. The sum-frequency angle θω3 in equations 2.8a-c and 2.9a-c for the nonlinear 
Fresnel coefficients can be determined by using the momentum conservation of the wave 
vectors and Snell’s law of refraction, such that: 
    kx(ω3) = kx1(ω1) + kx2(ω2) ,                   (4.7) 
where kx(ω3) , kx1(ω1) and kx2(ω2) are the wave vectors of the SFG, fundamental beam 
1, and fundamental beam 2, respectively. In the case where the fundamental beams 
propagate through the linear medium 𝑛𝑅 , the wave vectors kx1(ω1) and kx2(ω2) can be 
given by: 
    kx1(ω1) =  nR ω1 sinθ1c  ,                  (4.8a) 
    kx2(ω2) = nR ω2 sinθ2c  .              (4.8b) 
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Substitution of equations 4.8a-b into equation 4.7 yields: 
   kx3(ω3) = nR ω1 sinθ1 + nR ω2 sinθ2c  .                    (4.9) 
Therefore, the reflected θR
ω3  and transmitted θT
ω3  angles of the sum frequency beam are 
given by: 
   θR
ω3 = arcsin �nR ω1 sinθ1 + nR ω2 sinθ2
nR ω3
� ,               (4.10a) 
   θT
ω3 = arcsin �nR sinθR
ω3
nT ω3
� .                (4.10b) 
 Similar to SHG, a resonant enhancement in SFG can be achieved by tuning the 
fundamental frequencies, ω1, or ω2, or the SFG frequency, ω3, to approach the frequency 
of an optical transition (electronic/vibrational). This leads to an increase in the resonant 
χR




�hω3 - Eca - iΓca��hω1 - Eab - iΓab��hω2 - Ebc  - iΓbc�a,b,c  ,                       (4.11) 
 where N is the surface density of molecules, h is Planck’s constant, µ is the Cartesian 
coordinate dipole operator, Γ represents the linewidth of the transition, and a, b and c 
represent the initial, intermediate and final states, respectively (see Figure 4.1).1 
 The vibrational resonant enhancement feature of SFG has been exploited 
extensively to study molecular structures at interfaces, including water,3-5 surfactants,6-9 
proteins10-13 and lipid structures.14-16 The vibrational spectra of these interfacial structures 
are obtained with infrared-visible (IR-Vis) SFG in which the two input beams are a 
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Figure 4.1 Energy level diagram of sum-frequency generation process. 
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visible source at a fixed frequency and a tunable IR source. When the frequency of the IR 
is scanned through vibrational resonances of the molecules of interest, such as the C-H 
stretching modes or amide I region, a sum-frequency vibrational spectrum is obtained by 
recording the SFG intensity as a function of the IR frequency. 
 In addition to probing vibrational transitions, SFG can be utilized to probe 
electronic transitions by using ultraviolet and visible light sources (UV-Vis SFG). UV-
Vis SFG emission is in the deep UV range (194-237 nm) allowing the investigation of a 
variety of biological molecules that contain aromatic groups, such as amino acids, 
proteins and some drugs. A full description of UV-Vis SFG is presented in the following 
section. 
4.2 Ultraviolet-Visible (UV-Vis) Sum-Frequency Generation 
 UV-Vis SFG involves the spatial and temporal overlap of a UV source (355 nm) 
and a tunable visible source (430-710 nm). The resulting SFG occurs in the deep UV 
wavelength range (194-237 nm). For the work presented in this dissertation, a UV source 
at 355 nm was used in combination with a fixed visible source at 532 nm to generate a 
SFG output at 213 nm.  
A theoretical SFG response for both p- and s-output polarization can be calculated 
using the equations 4.6a-b described above. In the calculation, the 355 nm and 532 nm 
beams propagated through a silica medium (nsilica), arrived at a silica/water interface 
where they interacted and generated a sum-frequency beam at 213 nm, and then 
transmitted into a water medium (nH2O). A counter-propagating geometry was used in the 
calculation where the two fundamental beams approach the silica/water interface from 
opposite directions under total internal reflection (TIR) (Figure 4.2).  
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Figure 4.2 Schematic of a counter-propagating geometry used in the UV-Vis SFG 
calculation. The fundamental beams at 355 nm and 532 nm approach the silica/water 
interface from opposite direction with the incident angles θ1 and θ2, respectively. The 
sum frequency beam is generated at 213 nm in the reflection (θR





    
 
 In order to calculate the SFG response from equations 4.6a-b, the incident angles 
θ1 and θ2, polarization angles γ1 and γ2, linear and nonlinear Fresnel coefficients must be 
known. To satisfy the TIR condition used here, the incident angles of the 355 nm and 532 
nm beams must be greater than the critical angles, which can be determined by:   
    θc
355 = arcsin �nH2O
355
nsilica
355 � ,                     (4.12a) 
    θc
532 = arcsin �nH2O
532
𝑛silica
532 � ,         (4.12b) 
where nH2O355  and nH2O532  are the refractive indices of water for a wavelength of 355 nm and 
532 nm, respectively. nsilica355  and nsilica532  are the refractive indices of silica at a wavelength 
of 355 nm and 532 nm, respectively. The values of nH2O355 ,  nH2O532 , nsilica355  and nsilica532  are listed 
in Table 4.1. The calculated critical angles for the 355 nm and 532 nm beams are 66.85° 
and 66.25°, respectively. Therefore, the incident angles of the fundamental beams (θ355 
and  θ532) are both chosen at 67° for TIR to occur.  
 The reflected and transmitted angles for UV-Vis SFG, θR
213 and θT
213, can then be 
calculated using equations 4.10a-b as described previously: 
  θR
213 = arcsin �nsilica 
355 ω355 sinθ
355 + nsilica




� ,              (4.13a) 
  θT
213 = arcsin �nsilica
355  ω355 sinθ355 + nsilica532  ω532 sinθ532
nH2O
213  ω213
� .              (4.13b) 
The calculated values for θR
213  and θT
213  are 10.47° and 11.24°, respectively. Once the 
reflected θR
213  and transmitted θT
213  SFG angles are known, the nonlinear Fresnel 
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Table 4.1 Indices of refraction of fused silica and water at different wavelengths. 
Wavelength (nm) nsilica nwater 
213 1.5352 1.4312 
355 1.4761 1.3572 




    
 
coefficients f̃  Rand  f̃  T given in equations 2.8a-c and 2.9a-c can be determined. The linear 
Fresnel coefficients can be calculated from equations 2.5a-c described in Chapter 2. In 
the case of TIR geometry where the incident angles of the fundamental beams (θI
355 =  θI532 = 67°) are greater than their critical angles (θc355 = 66.85° and θc532 = 66.25°), the 
sine of the transmitted angles (sinθT
355 and sinθT
532) of the fundamental beams becomes 
larger than one and thus, the values of θT
355 and θT
532 become imaginary. 
 Now that the incident angles of the 355 nm and 532 nm beams (θI355 and  θI532), 
the nonlinear Fresnel f̃ coefficients and the linear Fresnel coefficients f are known, the p-
polarized and s-polarized SFG intensity (equations 4.6a-b) can be expressed in terms of 
the polarization angles of the fundamental beams, γ1 and γ2, and the susceptibility tensor 
elements. The polarization dependence of the SFG response can then be evaluated by 
calculating the SFG intensity as a function of γ1 and γ2. In this calculation, it is assumed 
that γ1 is equal to γ2 and the intensity of the 355 nm input I1 is the same as the intensity of 
the 532 nm input I2. Additionally, the calculation of the SFG response is only for an 
achiral surface possessing C∞v symmetry. The following values for the nonvanishing 
achiral χ(2) elements were selected according to Kriech and Conboy for achiral surfaces:17 
χxxz = 1 + i,  χxzx = 1 + i,  χzxx = 1 + i,  and χzzz = 2 + 2i.  
 The theoretical reflected p- and s-polarized SFG responses as a function of γ are 
shown in Figures 4.3a and b, respectively. The p-polarized SFG response for an achiral 
surface has two maxima at p (γ1 = γ2 = 0° and 180°) and two minima at s (γ1 = γ2 = 90° 
and 270°) input polarizations. The s-polarized response exhibits four identical peaks that 
have maxima at mixed input polarization (γ1 = γ2 =45°, 135°, 225° and 315°) and minima 
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Figure 4.3 Calculated reflected UV-Vis SFG response as a function of incident 
polarization angle γ for (a) p-polarized output and (b) s-polarized output.  
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at p (γ1 = γ2 = 0° and 180°) and s (γ1 = γ2 = 90° and 270°) input polarizations. It should be 
noted that the magnitude and shape of the p-polarized SFG response varies according to 
the values of the independent tensor elements in χ(2). The magnitude of the s-polarized 
SFG response also changes with the χxxz  and χxzx  tensor elements, however its 
polarization dependence response is independent of the values of the χxxz and χxzx tensor 
elements.  
 Similarly, theoretical transmitted p- and s-polarized SFG responses have the same 
polarization dependence as the reflected SFG responses. As s-polarized SFG intensity is 
maximized at mixed input polarization, and thus the intensity at the mixed input 
polarization will be utilized to monitor biomolecular interactions, which will be presented 
in the following chapter. 
4.3 Summary 
 In this chapter, the general principles of the nonlinear optical spectroscopy SFG 
were discussed. Similar to SHG, SFG is only allowed at surfaces or interfaces, under 
electric-dipole approximation, making the technique highly surface specific. 
Additionally, the resonant enhancement in SFG can be utilized as a sensitive and intrinsic 
probe to detect biomolecular interactions at a surface. The development of counter-
propagating UV-Vis SFG was also presented where the SFG wavelength is in the deep 
UV (194-237 nm) allowing the ability to detect amino acids, proteins and drugs 
containing aromatic rings/double bonds. In the next chapter, UV-Vis SFG will be used as 
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CHAPTER 5 
DETECTION OF DRUG-LIPID MEMBRANE INTERACTIONS                           
WITH UV-VIS SUM-FREQUENCY GENERATION  
5.1 Introduction 
 In Chapter 4, the development of UV-Vis SFG was presented where the SFG 
wavelength is in the deep UV (194-237 nm), allowing π → π* and n → π* electronic 
transitions to be probed in a variety of biological species such as aromatic amino acids, 
peptides, proteins and aromatic/double bond containing drugs. The application of UV-Vis 
SFG for a direct detection of drug associations into lipid membranes is described in this 
chapter. 
 Drug-membrane interactions play a crucial role in the pharmacology and activity 
of drugs.1-3 The equilibrium of a drug molecule between plasma and the cellular 
membrane has conventionally been characterized by bulk phase partitioning, usually 
between water and 1-octanol, which is used to mimic the lipid membrane.4-7 However, 
the bulk thermodynamic properties of a homogenous liquid phase, i.e., 1-octanol, cannot 
accurately model the thermodynamics of a lipid membrane, which is comprised of an 
approximately 50 Å thick lipid bilayer. Additionally, the membrane, composed of various 
phospholipids, proteins and cholesterol, is best described as a finite interfacial region 
with a very high surface-to-volume ratio and a limited number of binding sites.8,9 For this 
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reason, solution phase liposome based assays have been developed to more accurately 
model and study drug-membrane association.10-13  
Spectroscopic methods for detecting drug-membrane interaction such as UV-Vis 
absorbance spectroscopy,14,15 fluorescence,13,16-18 IR,19-21 Raman,22,23 NMR24-26 and 
ESR27-29 have all been utilized to measure drug interactions with solution phase vesicles. 
Such techniques require large quantities of drug and lipid, and usually involve a 
separation step to remove unbound drug from the solution prior to analysis. These 
requirements are necessary due to the limited sensitivity of the spectroscopic methods 
employed.  
The use of planar supported lipid bilayers (PSLBs) for measuring drug-membrane 
association has several advantages over solution phase vesicles, including the use of 
smaller solution volumes, elimination of the separation steps employed in liposome-
based assays, and in principle, ability to integrate into a high-throughput assay. However, 
in order to fully exploit the potential benefits of a PSLB assay, what is needed is a 
detection method with high sensitivity, a low limit of detection and the capability of 
measuring drug-membrane interactions at the interfacial level without interference from 
solution phase species. 
Several possible methods could be employed to measure drug-membrane 
interactions on surfaces. Surface enhancement vibrational techniques such as attenuated 
total reflection (ATR) IR30 and surface enhanced Raman scattering (SERS)31 are sensitive 
spectroscopic methods but they suffer from spectral congestion and the inability to 
selectively isolate the resonances of the drug molecule from the surrounding lipid matrix. 
Raman scattering incorporated with confocal microscopy has also been used in detection 
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of drug-liposome interactions.32,33 The confocal microscopy allows Raman scattering 
from individual lipid vesicles to be detected, eliminating the contribution from the lipid 
matrix. The technique, however, requires a high laser power and long integration time as 
the Raman scattering signal is intrinsically weak.34 Total internal reflection fluorescence 
is an extremely sensitive method, capable of single molecule detection limit. However, if 
the drug molecule of interest lacks any intrinsic fluorescence, an extrinsic fluorescent tag 
must be covalently attached to the molecule for detection.   
In this chapter, the use of a novel deep UV spectroscopic method, ultraviolet-
visible sum-frequency generation (UV-Vis SFG), has been implemented to directly detect 
drug association to lipid membranes without the need for chemical modification. As 
described in Chapter 4, an increase in the UV-Vis SFG signal will be observed when the 
incident or SFG frequency is resonant with electronic transitions of the molecules 
presenting at the interface. In this way UV-Vis SFG has the spectral characteristics of 
UV-Vis absorbance spectroscopy but with higher sensitivity and surface specificity.   
To demonstrate the ability of UV-Vis SFG to detect drug association to a 
membrane, four drugs were examined: ibuprofen, azithromycin, tolnaftate and tetracaine. 
The chemical structure of these compounds and their associated UV-Vis spectra are 
shown in Figure 5.1 and 5.2, respectively. These drugs were chosen as they belong to 
four important classes of known membrane associated drug compounds:21,35-37 non-
steroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungals and anesthetics. 
Ibuprofen, tolnaftate and tetracaine all contain a π-conjugated ring system in their 
structures, resulting in strong electronic transitions in the UV as shown in Figure 5.2. 
Azithromycin was chosen as it possesses only a single carbonyl bond, giving rise to a 
78 
 









Figure 5.1 Molecular structures of ibuprofen, tetracaine, azithromycin and tolnaftate. 
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Figure 5.2 Extinction coefficient spectra of ibuprofen (solid), tetracaine (short dash), 
azithromycin (long dash) and tolnaftate (dotted). 
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small absorbance at the deep UV (< 220 nm), which makes it a significantly weaker 
absorber compared to the other drugs examined.  
5.2.1 Materials 
5.2 Experimental 
 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) was obtained from Avanti 
Lipids and was used as received.  Ibuprofen, tetracaine, azithromycin and tolnaftate were 
purchased from Sigma Aldrich. All water used in the experiments was obtained from 
NanopureTM Infinity Ultrapure water system with a minimum resistivity of 18.2 MΩ-cm. 
Phosphate buffered saline (PBS) was made from Na2HPO4∙7H20 and NaCl at a 
concentration of 50 mM and 100 mM, respectively, in water. The PBS buffer was 
adjusted to a pH of 7.5 using NaOH. The drugs were dissolved in PBS pH 7.5 to the 
desired working concentration. 
 The substrates used for the preparation of the PSLBs and the UV-Vis SFG 
experiments consisted of custom manufactured full spectrum grade (IR/UV) fused silica 
prisms (Almaz Optics). The prism was mounted onto a custom built Teflon flowcell. The 
prisms were cleaned by immersion in a solution of 70 % sulfuric acid and 30 % hydrogen 
peroxide overnight. Prior to use, the prisms were rinsed with water and cleaned with an 
Ar plasma (Harrick Scientific Plasma Cleaner/Sterilizer) for 3 minutes. Following the 
plasma cleaning procedure, the prisms were rinsed thoroughly with Nanopure water.  
5.2.2 Small Unilamellar Vesicle (SUV) Preparation 
 A 1 mg/ml solution of DOPC in chloroform was evaporated under a stream of 
N2(g) and vacuum dried overnight to remove residual chloroform. The dried lipids were 
suspended in PBS pH 7.5 to a concentration of 0.5 mg/mL by vortexing followed by bath 
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sonication for 10 - 30 minutes to clarify. The prism used as PSLBs substrate was 
mounted on a flowcell (described in the following section). PSLBs were formed on the 
silica prism by vesicle fusion, which involved incubating the surface with the SUV 
solution for 30 minutes. The flowcell was then flushed with PBS pH 7.5 to remove any 
free lipid solution.   
5.2.3 UV-Vis SFG Setup 
 The 532 nm (2nd harmonic) and 355 nm (3rd harmonic) beams from a Nd:YAG 
laser (Continuum, Surelite II, 20 Hz) with a diameter of 3 mm and energies of 12 and 14 
mJ/pulse, respectively, were used for the UV-Vis SFG experiments. The Vis and UV 
beams (both at mixed polarization, γ = 45o) were incident on the surface in a counter-
propagating geometry, with each beam striking the silica/water interface at an angle 
slightly greater than the critical angle, which is approximately 67o. The UV and Vis were 
spatially and temporally combined at PSLBs of DOPC which was deposited on a fused 
silica trapezoidal prism, to generate a SFG beam at 213 nm. A schematic of the optical 
arrangement is shown in Figure 5.3. Optical filters were placed in the path of the emitted 
SFG light to remove any scattered UV and Vis light. Spectroscopic detection was 
accomplished with a photomultiplier tube and the signal processed with a boxcar 
integrator. 
5.2.4 Equilibrium Binding of Drugs to PSLBs 
 The SHG intensity was measured at various bulk concentrations of drugs, 
increasing from low to high. At each concentration, the SFG was recorded until a steady- 
state response was achieved. The SFG intensity was plotted versus the bulk drug 
concentration.   
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Figure 5.3 UV-Vis SFG cell showing the geometric arrangement of the UV, Vis and SFG 
beams. Also shown is representation of the polarization state of the incident and output 
fields denoted as the angle γ with respect to the propagation direction (k). 
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 As described in equations 4.6a-b and 4.11 in Chapter 4, the SFG intensity (ISFG) is 
proportional to N2 which is the surface density squared; therefore, the Langmuir isotherm 
used to fit the SFG intensity is expressed as: 
     ISFG
ISFG





 ,                    (5.1) 
where ISFG  is the measured SFG intensity as a function of the bulk tetracaine 
concentration C, Ka is the equilibrium association constant and ISFG Max is the maximum SFG 
intensity at surface saturation.  
 The Frumkin model takes account into the electrostatic interaction between 
charged molecules, which is given by:    
    ISFG
ISFG
 Max = �
KaC exp�2g�ISFG/RT�
1 + KaC exp�2g�ISFG/RT�
�
2
 ,                  (5.2) 
when g > 0, the interaction between the adsorbed molecules is attractive while a 
repulsive interaction is represented by g < 0. When g = 0, the Frumkin model becomes 
the Langmuir model. A statistical evaluation (F-test) was performed using SigmaPlot 
with a confidence level of 95% to determine the most appropriate model to be applied to 
the data.  
5.2.5 Extrapolation of Partition Coefficients of Azithromycin and                         
Tolnaftate for Liposome Membrane-Water System 
The partition coefficients of charged azithromycin and neutral tolnaftate for the 
liposome membrane-water system are not available in the literature. Thus, these values 
were obtained by extrapolating the known partition coefficients of several drugs (see 
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Tables 5.1, 5.2 and Figures 5.4, 5.5) which were available in the literature7 in both the 
octanol-water and liposome membrane-water systems. Using a value of logPocti  = 0.23 for 
azithromycin and a value of logPoctN  = 5.40 for tolnaftate,38 the extrapolated logPmem i and 
logPmem N  were calculated as 2.12 and 5.17. These values are those which appear in Table 
5.4 in the results and discussion section. 
5.3 Results and Discussion 
5.3.1 Association of Drugs into a DOPC Bilayer 
 The adsorption isotherms for ibuprofen, tetracaine, azithromycin and tolnaftate 
are presented in Figures 5.6, 5.7, 5.8 and 5.9. The results from a nonlinear least-square 
regression of the data in Figures 5.6-5.9, to equation 5.1 (Langmuir isotherm) or 5.2 
(Frumkin isotherm), are listed in Table 5.3. It was found that the Langmuir isotherm fit 
best to ibuprofen (F = 2.15, P = 0.22) and tolnafate (F = 2.07, P = 0.21) binding data 
whereas the Frumkin isotherm provides a better fit to tetracaine (F = 545, P = 0.00) and 
azithromycin (F = 8.39, P = 0.04) binding data. 
 The affinity constants, Ka, for the drugs examined here were found to increase in 
the order ibuprofen < tetracaine < azithromycin < tolnaftate. The order in the affinity 
constants measured by the UV-Vis SFG agrees with the order of the partition coefficient 
of the studied drugs in the liposome-water system (Pmemi ) listed in Table 5.4. In particular, 
a positive correlation was observed between the free energy of adsorption (∆Gads = - 
RTlnKa) and the free energy of transfer from water to liposome-membrane (∆Gtrans = - 
RTlnPmemi ) for each drug (see Table 5.4). This observation is not surprising as the main 
driving force for drug-membrane association and partitioning between water and 
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Table 5.1 Logarithm of partition coefficients of six ionized drugs in octanol-water 
 and liposome membrane-water systems.  
Drug logPocti  logPmem i  
Ibuprofen - 0.05 1.81 
Dichlofenac 0.69 2.64 
Warfarin - 0.46 1.38 
Lidocaine - 0.53 1.22 
Tetracaine 0.22 2.11 


















Table 5.2 Logarithm of partition coefficients of five neutral drugs in octanol-water 
 and liposome membrane-water systems.  
Drug logPoct N  logPmem N  
Ibuprofen 3.97 3.80 
Dichlofenac 4.51 4.45 
Metoprolol38 1.95 2.00 
Lidocaine 2.45 2.39 














































Figure 5.6 Corrected square-root of UV-Vis SFG intensity vs. bulk ibuprofen 
concentration. The solid line is the fit to the Langmuir isotherm. The error bars represent 
the standard deviation from three independent experiments. 
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Figure 5.7 Corrected square-root of UV-Vis SFG intensity vs. bulk tetracaine 
concentration. The solid line is the fit to the Frumkin isotherm. The error bars represent 
the standard deviation from three independent experiments. 
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Figure 5.8 Corrected square-root of UV-Vis SFG intensity vs. bulk azithromycin 
concentration. The solid line is the fit to the Frumkin isotherm. The error bars represent 

















Figure 5.9 Corrected square-root of UV-Vis SFG intensity vs. bulk tolnaftate 
concentration. The solid line is the fit to the Langmuir isotherm. The error bars represent 














Table 5.3 Measured equilibrium association constant, square-root of maximum SFG 
 intensity at surface saturation, and g values for various drugs. 
Drug Ka (M-1) �ISFG Max (a.u.)  g 
Ibuprofen (4.37 ± 0.33) × 104 0.66 ± 0.09  
Tetracaine (5.14 ± 0.01) × 104 1.88 ± 0.01 - 1.51 ± 0.06 
Azithromycin (1.25 ± 0.09) × 108 0.49 ± 0.05 - 6.51 ± 2.19 














Table 5.4 Partition coefficient in membrane-water system, transfer free energy, and 
 adsorption free energy for various drugs.        
Drug logPmemi  ∆Gtrans (kJ/mol) ∆Gads (kJ/mol) 
Ibuprofen 1.81 - 10.3 - 26.5 
Tetracaine 2.11 - 12.0 - 26.9 
Azithromycin 2.12* - 12.1 - 46.2 
Tolnaftate 5.17* - 29.5 - 50.5 
 *extrapolated values described in section 5.2.5 
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liposome-membrane is the hydrophobicity of the drug compounds.  It is important to note 
that the correlation is clearly not linear which points to the underling difficulties of 
obtaining drug-membrane binding affinities from equilibrium bulk partitioning data. In 
order to obtain binding affinities from bulk partition measurements, knowledge of the 
molar free-volumes of the solute and matrix is required.28 Additionally, binding 
saturation is never achieved in the bulk partition measurements due to the nature of the 
bulk phase with unlimited number of binding sites. The fact that UV-Vis SFG is able to 
obtain this information in a straightforward manner is therefore advantageous. 
 The obtained negative value of g for tetracaine and azithromycin illustrates the 
repulsive interactions between the charged drug molecules. At pH 7.5, tetracaine and 
azithromycin are both primarily positive charged while ibuprofen possesses one negative 
charge. However the Langmuir model provides a better fit to the adsorption data of 
ibuprofen, presumably due to the electrostatic shielding from the supporting electrolytes. 
This behavior was not observed for tetracaine and azithromycin, suggesting the 
electrostatic shielding could be more significant for ibuprofen. It has been reported that 
ionized ibuprofen (weak acid) locates closer to the membrane-water interface while the 
ionized tetracaine and azithromycin (weak bases) associate more strongly into the 
hydrophobic tails of the lipid membrane.39 Therefore, in order to screen the electrostatic 
interactions between the ionized tetracaine and azithromycin molecules, electrolyte 
species from the bulk phase have to move deeper into the membrane, which is not an 
energetically favorable process.39 The absence of any electrostatic repulsion is clearly 
seen for tolnaftate, which is the only neutral drug in this study and is best fit with a 
Langmuir isotherm (g = 0).  
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5.3.2 Calculation of Surface Excess of Drugs in a DOPC Bilayer 
In addition to retrieving information on the thermodynamics of drug-membrane 
association, the ability of UV-Vis SFG to obtain information about the surface excess of 
the drug Γmax in the membrane is also possible. As with other spectroscopic methods, the 
UV-Vis SFG response as a function of surface concentration needs to be calibrated. This 
could be achieved by using lipid membranes which have fixed and known concentrations 
of drug in the membrane and measuring the UV-Vis SFG response. As the drug-
membrane association is a dynamic equilibrium process, it is not possible to create such 
standards easily. However, data do exist, in the form of partition coefficients for the 
drugs in liposome-membrane systems or octanol-water partitioning data,7 which can be 
used to calibrate the UV-Vis SFG data. In the linear region of the binding isotherms, i.e., 
at low surface density, the partitioning of the drug in the membrane is identical to that in 
a bulk liquid phase as there is effectively no competition for binding sites.40 Using the 
linear regions of the isotherms shown in Figures 5.6-5.9, the UV-Vis SFG intensity was 
calibrated for each drug. The partition coefficients were used to determine the membrane 
concentration from the bulk aqueous concentration of the drug: 
   [Drug]mem = Pmemi [Drug]aqueous ,                  (5.3) 
where [Drug]mem and [Drug]aqueous are the concentrations of the drug in the membrane 
and aqueous phases, respectively. Pmemi  is the partition coefficient of the charged drug in 
the membrane. The surface concentration of the drugs in molecules (molc)/cm2 was then 
determined by assuming an effective thickness of the DOPC bilayer of 50 Å.      
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 The calculated surface excess Γ (in molc/cm2) is plotted as a function of bulk 
concentration for ibuprofen, tetracaine, azithromycin and tolnaftate in Figures 5.10, 5.11, 
5.12, and 5.13, respectively. The maximum surface excess of the drugs Γmax is given in 
Table 5.5. Although the affinity constants for the drugs are in the order ibuprofen < 
tetracaince < azithromycin < tolnaftate, the same cannot be said of the saturation 
concentration of the drugs in the membranes. Azithromycin has the lowest surface 
saturation, (1.58 ± 0.16) × 1010 molc/cm2 while tolnaftate is considerably larger, (1.00 ± 
0.03) × 1013 molc/cm2. Ibuprofen and tetracaine have similar surface saturation values, 
(0.92 – 2.08) × 1012 molc/cm2. The lowest maximum surface excess observed for 
azithromycin could be related to the lipid membrane disruption caused by azithromycin 
upon its interaction with the lipid membrane. It has been previously reported that 
azithromycin at a concentration of 50 µM was found to affect the elasticity of DOPC 
giant unilamellar vesicles (GUVs) by decreasing the cohesion between the DOPC 
molecules, resulting in a disruption of the GUVs of DOPC.41 The µM concentration 
range of azithromycin used in the present study could cause the disruption of the DOPC 
lipid bilayer, leading to the low maximum surface excess of azithromycin. 
 The absence of a direct link between Ka and Γmax is not surprising, as the factors 
determining these two quantities are not necessarily correlated. Ka is governed by the 
thermodynamic stability of the molecule in the membrane. However, the partition 
coefficient does not have any dependence on the number of binding sites, as it represents 
bulk equilibrium. Likewise, the value of Ka is not dependent on the absolute number of 
binding sites, but rather is a reflection of the fraction of surface occupancy at a specific 
bulk concentration; which is why knowledge of the affinity constant alone is not 
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Figure 5.10 Surface excesses Γ  vs. bulk concentration of ibuprofen. The solid line is the 
fit to the data using the Langmuir isotherm. The error bars represent the standard 
deviation from three independent experiments. 
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Figure 5.11 Surface excesses Γ  vs. bulk concentration of tetracaine. The solid line is the 
fit to the data using the Frumkin isotherm. The error bars represent the standard deviation 
from three independent experiments. 
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Figure 5.12 Surface excesses Γ  vs. bulk concentration of azithomycin. The solid line is 
the fit to the data using the Frumkin isotherm. The error bars represent the standard 
deviation from three independent experiments. 
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Figure 5.13 Surface excesses Γ  vs. bulk concentration of tolnaftate. The solid line is the 
fit to the data using the Langmuir isotherm. The error bars represent the standard 
deviation from three independent experiments. 
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Table 5.5 Maximum surface excess and limit of detection for various drugs.  
Drug Γmax (molecule/cm2) LOD (pg/cm2) 
Ibuprofen (9.22 ± 0.14) × 1011 46.9 ± 4.7 
Tetracaine (2.08 ± 0.01) × 1012 116.7 ± 10.9 
Azithromycin (1.58 ± 0.16) × 1010 3.6 ± 0.3 








    
 
sufficient to determine the absolute number of molecules bound to the membrane. A 
quantitative determination of drug saturation in the membrane is possible when both the 
data from bulk phase equilibrium measurements and UV-Vis SFG are used in 
combination, with the use of PSLBs, as demonstrated here. 
A quantitative assessment of the limit of detection (LOD) of UV-Vis SFG can 
also be made. Using the spectroscopic sensitivity determined from the calibration of the 
UV-Vis SFG intensity and the standard deviation in the measured signal, the detection 
limits for the three drugs examined were calculated by: 
    LOD = 3σ
sensitivity
                    (5.4) 
where σ is the average standard deviation from the background signals (in the absence of 
the drugs). The sensitivity in equation 5.4 was obtained from the calibrated SHG 
intensity. The calculated values of LOD are listed in Table 5.5. The lowest calculated 
LOD is 3.6 ± 0.3 pg/cm2 for azithromycin with the highest observed for tolnaftate at 1.31 
± 0.05 ng/cm2. The lowest calculated LOD obtained for azithromycin could be related to 
the highly ordered orientation of azithromycin in the DOPC lipid bilayer. The protonated 
form of azithromycin was found to penetrate into a monolayer of the negatively charged 
phosphatidylinositol lipid with the drug's desoamine group inserting into the hydrophobic 
cores of the lipid monolayer and the endocyclic tertiary amine staying closer to the 
negatively charged phosphate of the lipid head group.42 Another factor that could also 
contribute to the low calculated LOD of azithromycin is the larger asymmetry of the drug 
molecule as compared to the other drugs used in the study, which enables the detection of 
azithromycin to be done more easily. 
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 These detection limits are far superior to the other surface specific and label-free 
method, SPR, and are comparable to fluorescence measurements but without a label 
being needed and with reduced photo-degradation. The impressive LOD and the surface 
specificity of UV-Vis SFG illustrate the potential application of the method for 
measuring low-molecular weight drug-membrane interactions. 
5.3.3 Effect of Electrolyte Concentration on Drug Binding to a DOPC Bilayer 
In order to verify the repulsive interaction between the charged drug molecules, 
the UV-Vis SFG measurements were performed at two different salt concentrations of 
PBS for ibuprofen: 150 mM (100 mM NaCl + 50 mM Na2HPO4)  and 15 mM (10 mM 
NaCl + 5 mM Na2HPO4). The adsorption isotherms for ibuprofen at these two salt 
concentrations are shown in Figure 5.14. The equilibrium association affinity Ka, g and 
square-root of the maximum intensity, �ISFGMax  obtained are listed in Table 5.6. 
 As seen in Figure 5.14 and Table 5.6, the electrolyte concentration does not 
significantly affect the equilibrium association affinity of ibuprofen to DOPC bilayer. 
However, the electrostatic repulsion between the charged ibuprofen molecules is 
observed at low electrolyte concentration as demonstrated by negative value of g (-2.36 ± 
0.67). This is due to the increase in the Debye length at low electrolyte concentration (15 
mM PBS) or a decrease in the shielding strength, resulting in more repulsion between the 
charged ibuprofen molecules. Accordingly, the maximum surface excess, Γmax, for 












Figure 5.14 UV-Vis SFG isotherms for ibuprofen binding to a DOPC lipid bilayer in 150 
mM PBS (filled circles) and at 15 mM PBS (open circles). The lines are the fits to the 
data using the Langmuir isotherm (solid) and Frumkin isotherm (dash). The error bars 
represent the standard deviation from three independent experiments. 
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Table 5.6 Measured equilibrium association constant, square-root of maximum SFG 
 intensity at surface saturation, and g values for ibuprofen at different 
 electrolyte concentrations. 
Electrolyte concentration Ka × 104 (M-1) �ISFGMax  (a.u.) g 
100 mM NaCl + 50 mM Na2HPO4 4.37 ± 0.33  0.66 ± 0.09  
10 mM NaCl + 5 mM Na2HPO4 6.27 ± 1.43 0.55 ± 0.03 -2.36 ± 0.6 
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5.4 Summary 
 The detection of drug-lipid membrane association was directly achieved using 
UV-Vis SFG spectroscopy without chemical modification. The equilibrium association 
constants of ibuprofen, azithromycin, tolnaftate and tetracaine into a lipid membrane 
have been measured for the first time and have been shown to correlate with the drugs’ 
hydrophobicity. The concentration of the drugs in the lipid membrane was quantitatively 
obtained using the knowledge of bulk partition coefficients in combination with the UV-
Vis SFG measurements. The electrostatic repulsion between the charged ibuprofen 
became obvious when low electrolyte concentration was used. The detection limit of the 
technique of pg/cm2 and the surface specificity of UV-Vis SFG suggest that UV-Vis SFG 
is a valuable alternative in measuring the association of drugs to the membranes.  
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CHAPTER 6 
HIGH-THROUGHPUT SCREENING OF DRUG-LIPID MEMBRANE  
INTERACTIONS WITH SECOND HARMONIC 
 GENERATION IMAGING 
6.1 Introduction 
 In the previous chapter it was shown that the nonlinear optical spectroscopic 
technique, ultraviolet-visible sum frequency generation (UV-Vis SFG), is an 
ultrasensitive and powerful method for the detection of drug-lipid membrane interactions. 
The drug-lipid membrane interactions were studied with a single lipid species which was 
used to compose the membrane; however, biological membranes are composed of many 
types of  phospholipids along with other small molecules, such as cholesterol. Therefore, 
it is also important to study the effect of lipid membrane structure and composition on 
drug-lipid membrane interactions. Currently, this is a time consuming and costly task 
which requires a large number of experiments and samples. This chapter presents the use 
of second harmonic generation imaging in combination with micropatterned lipid bilayer 
arrays which allow for a simultaneous investigation of the influence of different bilayer 
phase states and cholesterol content on drug binding in a high-throughput manner. 
 Micropatterned lipid bilayer arrays (MLBAs) are a 2D assembly of planar 
supported lipid bilayers (PSLBs) patterned on a surface. MLBA can be created by micro-
contact printing,1 deep ultraviolet photolithography (UV),2 prepatterned substrates,3 a 
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combination of prepatterned substrates with a robotic spotter systems,4 and 2D and 3D 
microfluidics.5,6 Among these techniques, 3D microfluidics has proven to be a promising 
method for making patterned planar supported lipid bilayers (PSLBs).6 The microfluidic 
system delivers fluid to a discrete region on a substrate through a printhead with 
individually addressable microchannels within a polydimethylsiloxane (PDMS) substrate. 
This allows different lipid vesicle solutions to be introduced to the microchannels, thus 
forming an array of different PSLBs on a single substrate. The microfluidic system does 
not require the use of a prepatterned substrate because the PSLBs are effectively 
“corralled” into discrete microsized domains by the residual PDMS deposited on the 
substrate from the printhead. Prevention of lipid spreading can also be enhanced by 
introducing bovine serum albumin or polyelectrolytes after the deposition step to bind to 
the residual hydrophobic PDMS.7  
Several techniques have been successfully employed to detect drug-membrane 
interactions including UV-Vis,8 NMR,9,10 vibrational spectroscopies (IR, Raman),11,12 and 
fluorescence.13,14  However, most of these methods are not suitable to study MLBAs. 
Vibrational spectroscopic techniques require signal enhancement such as attenuated total 
internal reflection (ATR) IR15 or surface enhanced Raman scattering (SERS)16 if they are 
to be used for surface detection. Intrinsic fluorescence of drug molecules can be a useful 
probe if present, but self-quenching can influence the response at high concentrations of 
the drug.17 In the absence of intrinsic fluorescence, the covalent attachment of a 
fluorescent label to the drug is possible. However, such an alteration would severely 
change the drug’s structure and more likely than not its biological activity.18 The label-
free technique of surface plasmon resonance has also been applied to detect drug-lipid 
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membrane binding.19,20 In these studies, liposomes attached to a lipophilic functionalized 
gold surface were used as model membranes for drug binding.  
Counter-propagating SHG has previously been employed to measure the 
association of the chiral molecules ((R)-(+)-1,1’-bi-2-naphthol (RBN) and (S)-(+)-1,1’-
bi-2-naphthol (SBN)) into lipid bilayers.21 It has also been successfully applied to image 
chiral RBN and SBN adsorbed to a patterned lipid bilayer.22 In this study, SHG imaging 
is coupled with MLBAs to image drug-lipid membrane interactions directly for the first 
time in a high-throughput manner.  
 It has been previously discussed in Chapter 2 that an increase in SHG signal will 
be observed when the incident, ω, or SHG, 2ω, frequency is in resonance with an 
electronic transition of a molecules comprising at the interface. This can be used as an 
intrinsic probe to detect the presence of drug molecules in the lipid membrane if the drug 
has an electronic transition at the frequency of the incident or the SHG light. The SHG 
process, under the electric-dipole approximation, is not allowed in the bulk of the 
centrosymmetric medium but is allowed at a surface or interfacial region between two 
centrosymmetric media due to the break in symmetry of the bulk phases. This makes 
SHG a surface specific technique. It should be noted that the electric-quadrupole 
contribution from the bulk medium can contribute to the overall SHG signal.33,34 
However, its contribution can be neglected if the interfacial layer is highly symmetric23 
and/or the SHG frequency is in resonance with the electric-dipole allowed transitions of 
the interfacial layers.24 In these cases, the SHG signal should be governed principally by 
the electric-dipole contribution from the interfacial layer. The local anesthetic tetracaine 
(extinction coefficient spectrum and molecular structure were shown in Chapter 5) was 
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chosen as a model drug in the present study. As the SHG wavelength at 266 nm is 
resonant with the π→π* transition of the benzene ring of tetracaine adsorbed to a surface, 
the SHG intensity will be significantly enhanced, dominating over the bulk contribution. 
  The aim of the present work is to show that counter-propagating SHG imaging 
combined with MLBAs can be used as a label-free technique to visualize tetracaine-
membrane interactions in a high-throughput manner. Tetracaine's anesthetic activity 
mainly involves blocking Na+ influx through Na+ channels of the nerve axonal 
membranes.25 It is still unclear if the anesthetic mechanism depends on the direct 
interaction between the drug and its target protein or on the passive interaction between 
the drug and the surrounding membrane.26-28 In an attempt to elucidate this mechanism, 
several extensive studies investigating tetracaine-membrane interactions have been 
conducted. Specifically, the effects of tetracaine on the structure and dynamics of 
phospholipids were studied by FTIR29 and its effects on the phase behavior and 
thermodynamics of phospholipids were studied by differential scanning calorimetry.30 
The location of tetracaine in phospholipid vesicles has also been studied by fluorescence 
quenching and resonance energy transfer.31 Using the intrinsic fluorescence of tetracaine, 
the partitioning of tetracaine into lipid membranes was measured and found to depend on 
the physical state and composition of the lipids.14 Additionally, the ionization state of 
tetracaine was reported to affect its interaction with lipid membranes. It was found that 
neutral tetracaine partitions more strongly and deeply into zwitterionic phospholipids 
than the protonated tetracaine.14,29 It is important to mention that these studies were 




    
 
As a proof-of-principle investigation, the effects of the lipid phase state (solid-gel 
and liquid-crystalline) and membrane composition (saturated, unsaturated lipids, charged 
lipids and cholesterol content) on tetracaine binding were examined using SHG imaging. 
Using the MLBAs, multiple lipid membrane components with different phase states and 
cholesterol content were prepared on a single substrate allowing for simultaneous 
investigation of influence of these factors on tetracaine binding. Additionally, the binding 
of tetracaine in different charge states, including protonated and neutral, to the lipid 
bilayers were also examined. The results were found to correlate with the literature 
reports, validating the SHG imaging technique as a label-free and high-throughput 
method to detect drug-membrane interactions. Moreover, the study of tetracaine binding 
to the unsaturated lipids, which has not been previously published, reveals the crucial role 
that the phospholipid unsaturation plays in the binding affinity and surface concentration 
of tetracaine.   
6.2 Experimental 
6.2.1 Materials 
 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-
stearoyl-2-oleoyl-sn-glycero-3-phosphocholine(SOPC), 1,2-dioleoyl-3-trimethylammoni- 
um-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG) 
were obtained from Avanti Lipids and used as received. Tetracaine hydrochloride, 
cholesterol, poly(allylamine hydrochloride) (56,000 MW) and sodium dodecyl sulfate 
(SDS) were purchased from Sigma Aldrich. All water used in the experiments was 
obtained from a NanopureTM Infinity Ultrapure water system with a resistivity of 18.2 
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MΩ-cm. Phosphate buffered saline (PBS) was made from Na2HPO4∙7H20 and NaCl at a 
concentration of 50 mM and 100 mM, respectively, in water. The PBS buffer was 
adjusted to pH 7.4 using NaOH. Tetracaine hydrochloride was dissolved in PBS to 
working concentrations. The substrates used for the preparation of the MLBAs consisted 
of custom manufactured full spectrum grade (IR/UV) fused silica prisms (Almaz Optics). 
The prism was mounted onto a custom-built Teflon flowcell. The prisms were cleaned by 
immersion in a solution of 70% sulfuric acid and 30% hydrogen peroxide overnight. Prior 
to use, the prisms were rinsed with copious amounts of Nanopure water and cleaned with 
Ar plasma (Harrick Scientific Plasma Cleaner/Sterilizer, Ossining, NY) for 3 minutes. 
6.2.2 Small Unilamellar Vesicle (SUV) Preparation 
 Stock lipid solutions in chloroform were evaporated gently under a stream of 
N2(g) and vacuum dried overnight to remove residual chloroform.  The dried lipids were 
resuspended in PBS pH 7.4 at a concentration of 0.25 mg/mL by vortexing followed by 
bath sonication for 10 - 30 minutes until clear. The temperature during sonication was 
kept at least 10°C above the lipids’ phase transition temperature (Tm): room temperature 
for DOPC, DOPG and DOTAP (Tm = - 20°C) and SOPC (Tm = 6°C), 35°C for DMPC (Tm 
= 24°C), and 55°C for DPPC (Tm = 41°C). The molecular structures of these lipids and 
cholesterol are shown in Figure 6.1. 
6.2.3 MLBA Preparation 
 Details of the preparation of the MLBAs using the continuous flow microspotter 
(CFM) have been reported in detail elsewhere.6 Briefly, up to 48 spots (each spot is 400 × 
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400 µm2) can be produced by the CFM. The PDMS printhead was pretreated with 1.0 
mg/mL SDS in a 50:50 volume ratio of H2O and isopropyl alcohol solution for 30 
minutes and air dried. The clean prism was brought in contact with the pretreated PDMS 
printhead to create a pressure seal. Prior to lipid deposition, the microchannels were 
rinsed twice with a 50:50 solution of H2O and isopropyl alcohol and once with Nanopure 
water. The 0.25 mg/mL SUV solutions were simultaneously introduced through the 
microchannels and allowed to circulate over the prism for at least 20 minutes. The SUVs 
spontaneously fused to the hydrophilic substrate, forming an array of lipid bilayers. The 
free vesicle solutions were removed from the channels by rinsing with Nanopure water. 
The prism was removed from the PDMS printhead in a reservoir containing a solution of 
2 mg/mL polyallylamine in H2O and incubated for 20 minutes. The polyallylamine 
adsorbs to the PDMS residue from the printhead on the prism preventing the lipids from 
spreading. The prism was then transferred in water to a custom-built Teflon flow cell for 
imaging. The temperature in the flowcell was monitored using a water bath (Haake 
Phoenix II, Thermo Scientific). 
6.2.4 SHG Imaging 
 Counter-propagating SHG imaging was used in this work for the detection of the 
tetracaine-lipid membrane interactions. The 2nd harmonic output (532 nm) of a Nd:YAG 
laser (Continuum, Surelite I, 20 Hz, 7ns) with an energy of 22 mJ/pulse was directed on 
the surface of a quartz prism under total internal reflection. A laser beam diameter of 3.5 
mm was used. The reflected beam from the surface is reflected back upon itself using a 
532 nm mirror. This results in two incident beams at the same frequency arriving at the 
surface from opposite directions, both with an incident angle of 67° to ensure total 
118 
 
    
 
internal reflection. The schematic of the optical arrangement was previously shown in 
Chapter 3. A slight displacement of the reflected beam is introduced in order to prevent 
the redirected beam from entering the laser cavity.  
 The resulting SHG is emitted at 266 nm along the surface normal and optically 
filtered to remove any scattered visible light prior to imaging. Imaging of the SHG signal 
was achieved using a modified Olympus microscope22 with a 3× UV objective (Optics 
for Research). An image intensifier (Phototek) coupled to a CCD camera (Roper 
Scientific, 512 × 512 pixels) was used for image acquisition. An integration time of 1200 
seconds was used to collect all SHG images. SHG images were analyzed and false-color 
applied using the software package imageJ (http://rsbweb.nih.gov/ij/index.html). Each 
SHG image was first background corrected by subtracting the minimum pixel intensity 
from the image. The image was then flat-field corrected using the ImageJ macro available 
at the Integrated Microscopy Core Facility at the University of Chicago 
(http://digital.bsd.uchicago.edu/%5Cimagej_macros.html). The SHG images were 
normalized to allow for a direct comparison between the images recorded from different 
experiments.  
6.2.5 Normalization of SHG Images 
 In order to obtain accurate and statistically meaningful results from the SHG 
experiments, normalization of the image data was performed in order to directly compare 
SHG images recorded from different experiments.  An internal calibration procedure was 
conducted after the completion of each experiment by using the SHG intensities 
measured from a continuous DOPC bilayer measured first in pure PBS and then in a 0.83 
mM solution of tetracaine in PBS at pH 7.4. Prior to depositing the continuous DOPC 
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bilayer, a 0.1 M KOH solution was injected in the flowcell for 30 minutes to destroy the 
MLBA and remove all adsorbed species from the substrate. The SHG image was then 
normalized using the following equation: 
  Normalized image = flat-field corrected image - Io
SHG
ITec
SHG - IPBSSHG × constant ,      (6.1) 
where IoSHG is the average SHG intensity obtained from the two DOPC spots in each array 
in PBS at pH 7.4 (before adding tetracaine),  IPBSSHG and ITecSHG  are the SHG intensities 
measured from the continuous DOPC bilayer in PBS pH 7.4 before and after introducing 
0.83 mM tetracaine (in PBS at pH 7.4), respectively.  
6.2.6 Equilibrium Binding Affinity of Tetracaine 
 The SHG images were collected at various bulk concentrations of tetracaine, 
increasing from low to high. Each concentration was allowed to incubate for at least 30 
minutes before imaging to insure tetracaine binding to the lipid bilayer had reached 
equilibrium. The SHG intensity for each lipid component was plotted versus tetracaine 
concentration.   
 As described in equations 2.17 and 2.19 in Chapter 2, the SHG intensity (ISHG) is 
proportional to N2 which is the surface density squared; therefore, the Langmuir isotherm 
used to fit the integrated SHG intensity from each spot on the MLBA is expressed as: 
     ISHG
ISHG
 Max  = � KaC 1 + KaC �2 ,                   (6.2) 
where ISHG  is the measured SHG intensity as a function of the bulk tetracaine 
concentration C, Ka is the equilibrium association constant and ISHG Max  is the maximum 
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SHG intensity at surface saturation. The Frumkin model takes account into the 
electrostatic interaction between charged molecules, which is given by: 
    ISHG
ISHG
 Max  = � KaC exp�2g�ISHG/RT�1 + KaC exp�2g�ISHG/RT��2 ,                                  (6.3) 
when g > 0, the interaction between the adsorbed molecules is attractive while a 
repulsive interaction is represented by g < 0. When g = 0, the Frumkin model becomes 
the Langmuir model. A statistical evaluation (F-test) was performed using SigmaPlot 
with a confidence level of 95% to determine the most appropriate model to be applied to 
the data. 
6.3 Results and Discussion 
MLBAs composed of eight different lipid components were used to examine the 
effect of lipid physical state and the presence of cholesterol on tetracaine binding in PBS 
buffer (100 mM NaCl and 50 mM Na2HPO4) at physiological pH 7.4. The pKa of 
tetracaine in an aqueous solution is ~ 8.4814 so the tetracaine used in this study is mostly 
positively charged at pH 7.4. Four primary lipid components, DOPC, SOPC, DMPC and 
DPPC, were examined with and without 28 mol % cholesterol. These different lipid 
compositions were deposited in a 5 column, 3 row array for a total of 15 individual spots. 
In each column of the array, the primary lipid component was prepared in duplicate while 
the same lipid containing cholesterol was deposited once. The last spot in column 1 is the 
control where no lipid was deposited. The positions of the lipid bilayer spots were kept 
consistent throughout this work. It should be noted that the two first DOPC spots in 
column 1 were not used in the calculation. These two spots, labeled with a fluorescent 
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dye rhodamine (Rh), were used to locate the position of the lipid bilayer spots in the array 
before imaging with the microscope.  
6.3.1 Effect of Lipid Physical State  
The effect of the lipid physical state on tetracaine binding was examined by 
comparing the relative adsorption of tetracaine to DOPC, SOPC, DMPC and DPPC 
bilayers which correspond to the lipid spots at the following positions in the array: 2A, 
2B (DOPC, 18:1), 3A, 3B (SOPC, 18:0-18:1), 4A, 4D (DMPC, 14:0) and 5A, 5B (DPPC, 
16:0), shown in Figure 6.2. The numbers in the parenthesis represent the number of 
carbons in the acyl chain followed by the number of double bonds in the acyl chain. The 
experiments examining the effect of lipid physical state were conducted at 18°C, 27°C 
and 46°C. At 18°C, DOPC and SOPC are in the liquid-crystalline (lc) phase while DMPC 
and DPPC are in the solid-gel phase. When the temperature increases to 27°C, DOPC, 
SOPC and DMPC are in the lc phase while DPPC is in the gel phase. At 46°C, all the 
lipids are in the lc phase.  
The effect of the lipid physical state was first investigated at 18°C. The SHG 
images of tetracaine binding to DOPC, SOPC, DMPC and DPPC bilayer spots at this 
temperature are represented in Figure 6.2. As the concentration is increased, more 
tetracaine associates into the lipid bilayers causing the intensity at each lipid bilayer spot 
to increase. The control spot (1C) remains unchanged over the concentration range 
confirming the specific binding of tetracaine to the lipid bilayers. The binding curves of 
tetracaine to DOPC, SOPC, DMPC and DPPC bilayers are shown in Figure 6.3. The data 
presented in the figure are the average of four bilayer spots from two independent arrays 
(two spots in each array). These data were best fit by the Langmuir isotherm model 
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Figure 6.2 Normalized SHG images of tetracaine binding to a multicomponent lipid 
bilayer array which contains the following lipid compositions:  DOPC (1A, 1B, 2A, 2B); 
no lipids, control spot (1C) labeled by the white box; DOPC + 28 mol % cholesterol 
(2C); SOPC (3A, 3B); SOPC + 28 mol % cholesterol (3C); DMPC (4A, 4B); DMPC + 28 
mol % (4C); DPPC (5A, 5B); DPPC + 28 mol % cholesterol (5C). Each image represents 
a different bulk tetracaine concentration: 0 mM (a); 0.05 mM (b); 0.11 mM (c); 0.21 mM 
(d); 0.42 mM (e); 0.83 mM (f); 1.59 mM (g), and 3.32 mM (h). The images were 
collected at 18°C. Each bilayer patch is approximately 400 µm × 400 µm.   
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Figure 6.3 Normalized SHG intensities from the images in Figure 6.2 for the following 
lipid compositions: DOPC (circles), SOPC (squares), DMPC (upright triangles), and 
DPPC (inverted triangles). The lines are fits to the Langmuir adsorption isotherm model. 
The error bars represent the standard deviations from two independent bilayer arrays with 
two lipid spots in each array.  
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(equation 6.2) and the extracted equilibrium binding affinities are given in Table 6.1. It is 
assumed that a monolayer of tetracaine is formed in the lipid bilayer based on several 
factors. First, it has been previously proposed that tetracaine is present mainly in the outer 
leaflet of the lipid bilayer where the positive dimethylammonium group of tetracaine lies 
close to the negative phosphate group of the lipid interfacial region.32 This proposed 
bilayer location is supported by an NMR study showing that no flip-flop of tetracaine 
across the lipid bilayer occurs.32 Additionally, if tetracaine is present in both the inner and 
outer leaflets, the dipole moments of tetracaine in the two leaflets would cancel out, 
resulting in no net change in the SHG signal. In this study, an increase in the SHG 
intensity was observed with increasing tetracaine concentration up to 3.2 mM, suggesting 
that tetracaine binds as a monolayer in one leaflet of the bilayer. However, at 
concentrations above 3.2 mM, the intensity began to decrease which could be attributed 
to the binding of tetracaine into both leaflets of the bilayer. Although the decrease in the 
SHG intensity can be ascribed to the dipole moment cancellation of tetracaine, it is 
possible that the decrease in the intensity is due to the disruption of the lipid bilayer 
caused by high concentration of tetracaine.33 Nonetheless, the binding data exhibit one 
plateau at saturation as opposed to multiple plateaus which indicates that a single 
adsorbed tetracaine layer is formed in the lipid bilayer. Collectively, from this 
information it can be inferred that the measured SHG signal in these experiments is from 
a monolayer of tetracaine inserting into one leaflet of the lipid bilayer. 
 Tetracaine binding to DMPC and DPPC bilayer spots at 18°C does not reach 
saturation over the concentration range used in this study, as seen in Figure 6.3, and thus 
it was not able to obtain the binding affinity of tetracaine to gel phase DMPC and DPPC. 
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Table 6.1 Measured binding affinity of tetracaine to lipid bilayers at different 
 temperatures. 
Lipid bilayer 
Ka × 104 (M-1) 
18°C 27°C 46°C 
DOPC 2.9 ± 0.2 1.3 ± 0.1 0.78 ± 0.08 
SOPC 2.8 ± 0.5 1.4 ± 0.1 0.83 ± 0.04 
DMPC N.A. 0.53 ± 0.07 0.55 ± 0.08 




    
 
Although the tetracaine binding cannot be quantitatively assessed, it is qualitatively 
observed that the binding affinity of tetracaine to DMPC and DPPC at this temperature 
would be the lowest of the lipids in this study. The data in Table 6.1 show that the 
binding affinity, Ka, of tetracaine at 18°C to the lipids in this study increases in the order 
DPPC ≈ DMPC < SOPC ≈ DOPC. At 18 °C, DOPC and SOPC are in the lc phase while 
DMPC and DPPC are in the gel phase. The higher Ka of tetracaine to DOPC and SOPC 
suggests that tetracaine associates into the lc phase lipids to a greater extent than into the 
gel phase lipids DMPC and DPPC. This is due to the fact that lipids in the lc phase are 
more loosely packed (~ 60-75 Å2/molecule34) which allows tetracaine to partition into the 
bilayer more easily than the tightly packed solid-gel phase (~ 45-50 Å2/molecule34). The 
association behavior of tetracaine reported here is consistent with literature reports that 
tetracaine incorporates more readily into lc DMPC14,31 and DPPC20 liposomes as 
compared to lipids in gel phase. This same trend has been observed for other local 
anesthetic drugs, including dibucaine, bupivacaine and lidocaine.35  
 To further examine the impact of lipid phase on tetracaine binding, the same 
experiment was performed at a higher temperature, 27°C. The SHG images of tetracaine 
binding to the MLBA and the binding curves at this temperature are shown in Figures 6.4 
and 6.5, respectively. Upon increasing the temperature from 18°C to 27°C, DMPC goes 
from the gel phase to the lc phase which allows tetracaine binding to DMPC to 
significantly increase. It should be noted that tetracaine binding to DPPC bilayer spots at 
27°C still does not reach saturation (Figure 6.4) and it can be deduced that the binding 
affinity of tetracaine to DPPC at this temperature would be the lowest relative to the other 
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Figure 6.4 The normalized SHG images of tetracaine binding to a multicomponent lipid 
bilayer array which contains the following lipid compositions:  DOPC (1A, 1B, 2A, 2B); 
no lipids, control spot (1C) labeled by the white box; DOPC + 28 mol % cholesterol 
(2C); SOPC (3A, 3B); SOPC + 28 mol % cholesterol (3C); DMPC (4A, 4B); DMPC + 28 
mol % (4C); DPPC (5A, 5B); DPPC + 28 mol % cholesterol (5C). Each image represents 
a different bulk tetracaine concentration: 0 mM (a); 0.05 mM (b); 0.11 mM (c); 0.21 mM 
(d); 0.42 mM (e); 0.83 mM (f); 1.59 mM (g), and 3.32 mM (h). The images were 
collected at 27°C.  Each bilayer patch is approximately 400 µm × 400 µm.   
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Figure 6.5 Normalized SHG intensities from the images in Figure 6.4 for the following 
lipid compositions: DOPC (circles), SOPC (squares), DMPC (upright triangles), and 
DPPC (inverted triangles). The lines are fits to the Langmuir adsorption isotherm model. 
The error bars represent the standard deviations from three independent bilayer arrays 
with two lipid spots in each array.  
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lipids in the study. The Ka of tetracaine to the DOPC, SOPC, DMPC and DPPC at 27°C is 
listed in Table 6.1 and increases in the order DPPC < DPMC < DOPC ≈ SOPC.   
 Similarly, when the temperature is increased to 46°C and DPPC enters the fluid 
phase there is an increase in tetracaine binding as illustrated in Figures 6.6 and 6.7. The 
Ka of tetracaine to DOPC, SOPC, DMPC and DPPC at 46°C is listed in Table 6.1. The Ka 
increases in the order DPPC < DMPC < DOPC ≈ SOPC. Interestingly, the Ka of 
tetracaine binding to the unsaturated lipids (DOPC and SOPC) is much greater than for 
the saturated lipids (DMPC and DPPC) when all the lipids are in the fluid phase.  This 
could be related to the difference in the molecular packing of the unsaturated and 
saturated lipids. The cis double bond in the unsaturated lipids results in a larger area per 
molecule (~ 75 Å2/molecule for lc phase DOPC34) as compared to the saturated lipids (~ 
67 Å2/molecule for lc DPPC34). Accordingly, the more loosely packed unsaturated lipids 
may allow more tetracaine binding. Surprisingly, very little work regarding tetracaine or 
other local anesthetic-lipid membrane interactions has been reported in the literature 
using unsaturated lipids, despite the fact that the lipids in cellular membranes are 
predominantly unsaturated.36 Instead, saturated DMPC and DPPC are commonly used in 
tetracaine and other local anesthetic membrane studies.10,14,37  
 A significant reduction in teracaine binding to DOPC and SOPC was observed 
when the temperature increased from 18°C to 27°C and 46°C. The decrease in drug 
partitioning into fluid lipids at elevated temperatures was also reported by Wright et al. 
who found teniposide, an anticancer agent, partitioning into DOPC gradually decreases 
with increasing temperature above the lipid’s phase transition temperature.38 Liu and 
coworkers reported the effect of temperature on the decrease in the partition coefficients 
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Figure 6.6 Normalized SHG images of tetracaine binding to a multicomponent lipid 
bilayer array which contains the following lipid compositions:  DOPC (1A, 1B, 2A, 2B); 
no lipids, control spot (1C) labeled by the white box; DOPC + 28 mol % cholesterol 
(2C); SOPC (3A, 3B); SOPC + 28 mol % cholesterol (3C); DMPC (4A, 4B); DMPC + 28 
mol % (4C); DPPC (5A, 5B); DPPC + 28 mol % cholesterol (5C). Each image represents 
a different bulk tetracaine concentration: 0 mM (a); 0.05 mM (b); 0.11 mM (c); 0.21 mM 
(d); 0.42 mM (e); 0.83 mM (f); 1.59 mM (g), and 3.32 mM (h). The images were 
collected at 46°C. Each bilayer patch is approximately 400 µm × 400 µm.   
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Figure 6.7 Normalized SHG intensities from the images in Figure 6.6 for the following 
lipid compositions: DOPC (circles), SOPC (squares), DMPC (upright triangles), and 
DPPC (inverted triangles). The lines are fits to the Langmuir adsorption isotherm model. 
The error bars represent the standard deviations from three independent bilayer arrays 




    
 
of beta blockers such as propranolol, alprenolol, and pindolol.39 Additionally, a decrease 
in the partitioning of dopamine antagonists into fluid lipid bilayers with increasing 
temperature was  obtained by Sarmento et al.40 A possible explanation is that the water 
solubility of hydrophobic drugs increases with temperature resulting in the decrease in 
the membrane partitioning.38,39 Another reason could be related to the conformational 
change in the lipid head group induced by temperature.38,40,41 As the temperature 
increases, the positively charged amine of the phosphocholine head group, which 
normally remains parallel to the lipid bilayer surface,  moves deeper into the hydrophobic 
core of the bilayer,41 where tetracaine is located. The electrostatic repulsion between the 
amine group and protonated tetracaine could repel tetracaine from the lipid bilayer. 
A quantitative comparison can be made between the measured binding affinities 
of tetracaine in this work and the values obtained by the UV-Vis SFG in Chapter 5 and 
the values published in the literature. Using UV-Vis SFG spectroscopy, an affinity of 5.1 
± 0.1 × 104 was measured for tetracaine binding to a DOPC bilayer (at room temperature) 
(see Chapter 5).42,43 In this work, a slightly smaller value (1.3 ± 0.1 × 104) was obtained 
for tetracaine associated into a DOPC bilayer at 27°C. Additionally, the adsorption 
models used to fit the data in the two studies are different. The Frumkin model fit best to 
the data in the previous study with a g value of -1.51 demonstrating the electrostatic 
repulsion between the charged tetracaine molecules. However, it was found that the 
Langmuir model was the statistically better fit to the data obtained by the SHG imaging. 
The difference between the Frumkin and Langmuir models is most pronounced at surface 
coverage below saturation. At low surface coverage, i.e., at low bulk tetracaine 
concentrations, the low signal/noise ratio in the SHG imaging data is not sufficient for the 
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nonlinear regression to identify the Frumkin behavior in the isotherm. On the other hand, 
the higher signal/noise ratio in the UV-Vis SFG experiment allows the Frumkin behavior 
in the isotherm to be statistically discerned as determined from a F-test analysis of the 
two models.  
There are several factors that contribute to the lower signal/noise ratio in the SHG 
imaging data. The most significant difference between the two experiments is the 
illuminated sample area. For the UV-Vis SFG experiments a continuous bilayer was 
examined with an illumination area of approximately 18 mm2 compared to the 0.16 mm2 
dimensions of the lipid spots in the current study with SHG imaging. As the SHG signal 
is proportional to the surface density squared, the two orders of magnitude decrease in the 
surface area of the lipid bilayer spots compared to the UV-SFG study will decrease the 
SHG signal by four orders of magnitude. Additionally, the sensitivity of the photocathode 
of the solar blind photomultiplier tube (~ 60 mA/W) used to collect the UV-Vis SFG 
signals is twice that of the image intensifier (~ 30 mA/W) used in the SHG imaging; thus, 
the measured SHG intensity is further reduced by a factor of two.  
In another study, Zhang et al. obtained a partition coefficient of (1.18 ± 0.2) × 104 
for DMPC (at 30°C) and (1.31 ± 0.13) × 104 for DPPC (at 45°C) at pH 5.5 (tetracaine is 
completely protonated).14 In this work, a binding affinity of (0.53 ± 0.07) × 104 M-1 and 
(0.24 ± 0.08) × 104 M-1 were obtained for fluid DMPC (at 27°C) and DPPC (at 46°C), 
respectively. The difference between these values can be related to the models used to 
describe the interactions between tetracaine and lipid membrane. Zhang and coworkers 
employed a partitioning equilibrium model to study tetracaine and lipid membrane 
interaction with an unlimited number of binding sites in the membrane. The data 
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presented here were described by the Langmuir model, which has been proposed to be 
the more suitable model to characterize tetracaine-lipid membrane interaction.31 
Additionally, the 3D structure of the lipid vesicles used in Zhang’ study could be more 
flexible thereby accommodating more tetracaine molecules as compared to the 2D 
structure of the planar supported lipid bilayers used here.  
 In addition to retrieving the binding affinity of tetracaine to lipid membranes, the 
maximum surface excess Γmax of tetracaine in the membrane can be assessed using the 
SHG binding curves and the bulk partition coefficient of tetracaine as described 
previously in Chapter 5.42 Knowledge of the surface excess of the drug in the membrane 
is essential in determining the bioavailability of the drug to the targeted protein that is 
embedded in the membrane. It is important to point out that this information cannot be 
determined solely from the partition coefficient data. The calculated Γmax of tetracaine in 
DOPC, SOPC, DMPC and DPPC bilayers at 18°C, 27°C and 46°C is given in Table 6.2. 
In general, the Γmax of tetracaine in the unsaturated lipid bilayers (DOPC and SOPC) is 
greater than in the saturated lipids bilayers (DMPC and DPPC). This is consistent with 
the higher binding affinity of tetracaine to the unsaturated lipids as compared to the 
saturated lipids. This behavior illustrates the correlation between the existence of double 
bonds in the lipid acyl chains and the resulting increase in the area per lipid molecule and 
an increase in tetracaine association. The effect of temperature on the Γmax of tetracaine, 
however, is not significant. As the temperature increases from 18°C to 27°C and 46°C, the 
Γmax of tetracaine in DOPC and SOPC does not significantly change, in contrast to the 
considerable reduction in the binding affinity of tetracaine to these lipids. This suggests 
that the molecular packing of the lipid membrane primarily governs the amount of 
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Table 6.2 Maximum surface excess of tetracaine in lipid bilayers.  
Lipid bilayer 
Γmax × 1012 (molecule/cm2) 
18°C 27°C 46°C 
DOPC 9.68 ± 0.08 8.63 ± 0.08 8.71 ± 0.08 
SOPC 10.0 ±0.16 8.23 ± 0.08 9.11 ± 0.08 
DMPC N.A. 6.37 ± 0.16 5.56 ± 0.24 




    
 
tetracaine adsorbed at saturation. When the lipids are in the fluid phase, the maximum 
surface excess is unaffected by temperature.   
6.3.2 Effect of Cholesterol on Tetracaine Binding 
  The effect of 28 mol % cholesterol on tetracaine binding was investigated using 
the lipid bilayer spots at the following positions in the array: 2C (DOPC + CHO), 3C 
(SOPC + CHO), 4C (DMPC + CHO) and 5C (DPPC + CHO) at 18°C, 27°C and 46°C in 
Figure 6.2, 6.4 and 6.6, respectively. The binding curves for these lipids compositions are 
shown in Figure 6.8, 6.9 and 6.10. For comparison, the binding curves for the pure lipids 
were also re-plotted in the same figures. The binding affinities at 18°C, 27°C and 46°C are 
given in Table 6.3. It should be noted that the binding affinities of tetracaine to DMPC in 
the presence of cholesterol are lower than that of the pure lipid at 18°C. Similarly, the 
SHG response from the binding of tetracaine to DPPC bilayer containing cholesterol is 
lower than that of the pure lipid at both 27°C and 46°C. Accordingly, it can be inferred 
that cholesterol reduces the binding of tetracaine into DMPC bilayer at 18°C and DPPC 
bilayer at both 27°C and 46°C. 
 The incorporation of 28 mol % cholesterol into the lipid bilayers does not have 
any effect on tetracaine binding to DOPC but does decrease tetracaine binding to SOPC, 
DMPC and DPPC in the temperature range used. In particular, cholesterol decreases the 
Ka of tetracaine to SOPC 68 %, 40% and 10% at 18°C, 27°C and 46°C, respectively, as 
compared to the pure lipid. In DMPC, the Ka of tetracaine in the presence of cholesterol 
is reduced by 42% and 60% at 27°C and 46°C, respectively. The reduction in tetracaine 
binding caused by cholesterol has been previously reported.10,14 Auger et al. found that 
the addition of 30 mol % cholesterol into fluid DMPC decreases the partition coefficient 
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Figure 6.8 Normalized SHG intensities at 18°C for the following lipid compositions: (a) 
DOPC + 28 mol % cholesterol (open circles),  DOPC (filled circles); (b) SOPC + 28 mol 
% cholesterol (open squares), SOPC (filled squares); (c) DMPC + 28 mol % cholesterol 
(open upright triangles), DMPC (filled upright triangles); and (d) DPPC + 28 mol % 
cholesterol (open inverted triangles), DPPC (filled inverted triangles). The lines are fits to 
the Langmuir adsorption isotherm model for the pure lipids (solid) and lipids containing 
cholesterol (dash). The error bars represent the standard deviations from two independent 
bilayer arrays with one lipid spot in each array.   
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Figure 6.9 Normalized SHG intensities at 27°C for the following lipid compositions: (a) 
DOPC + 28 mol % cholesterol (open circles), DOPC (filled circles); (b) SOPC + 28 mol 
% cholesterol (open squares), SOPC (filled squares); (c) DMPC + 28 mol % cholesterol 
(open upright triangles), DMPC (filled upright triangles); and (d) DPPC + 28 mol % 
cholesterol (open inverted triangles), DPPC (filled inverted triangles). The lines are fits to 
the Langmuir adsorption isotherm model for the pure lipids (solid) and lipids containing 
cholesterol (dash). The error bars represent the standard deviations from three 









Figure 6.10 Normalized SHG intensities at 46°C for the following lipid compositions: (a) 
DOPC + 28 mol % cholesterol (open circles),  DOPC (filled circles); (b) SOPC + 28 mol 
% cholesterol (open squares), SOPC (filled squares); (c) DMPC + 28 mol % cholesterol 
(open upright triangles), DMPC (filled upright triangles); and (d) DPPC + 28 mol % 
cholesterol (open inverted triangles), DPPC (filled inverted triangles). The lines are fits to 
the Langmuir adsorption isotherm model for the pure lipids (solid) and membranes 
containing cholesterol (dash). The error bars represent the standard deviations from three 














Table 6.3 Measured binding affinity of tetracaine to lipid bilayers containing 28 mol 
 % cholesterol at different temperatures. 
Lipid bilayer 
Ka × 104 (M-1) 
18°C 27°C 46°C 
DOPC + CHO 2.7 ± 0.5 1.2 ± 0.1 0.76 ± 0.08 
SOPC + CHO 0.89 ± 0.25 0.82 ± 0.06 0.75 ±0.11 
DMPC + CHO N.A. 0.31 ± 0.05 0.22 ± 0.05 
DPPC + CHO N.A. N.A. N.A. 
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of tetracaine in both the neutral and charged forms.10 Zhang et al. observed a decrease on 
the partition coefficient of tetracaine to DPPC bilayer below and above its phase 
transition temperature with 28 mol % cholesterol in the bilayer.14 The same effect has 
also been observed for other small molecules partitioning into lipid membranes.38,39,44  
 The addition of 28 mol % cholesterol, in the temperature range used in this study 
(18°C - 46°C), puts DOPC and SOPC in a liquid ordered phase (lo),45,46 which exhibits 
high fluidity as the liquid-crystalline phase but still possesses highly ordered acyl chains 
similar to those in the condensed phase.47 On the other hand, for the binary mixtures of 
DMPC + CHO and DPPC + CHO, there is a phase coexistence between a solid ordered 
(so) and liquid ordered (lo) below the Tm of the lipid and a liquid disordered (ld) phase 
coexists with a liquid ordered (lo) phase above the Tm.48-50 It has been reported that phase 
segregation occurs between the so phospholipid-rich domains and the lo cholesterol-rich 
domains, with a domain size in the range of ~ 18 nm51,52 to few µm.53 Although the lo and 
ld domains do coexist in a binary mixture of phospholipid and cholesterol, there are still 
questions as to whether or not the phase separation between the lo phase and ld phase 
occurs.54-56 However, the nm-µm domain size in the so - lo phases is too small to be 
identified in this work as the resolution of the SHG images limited by the image 
intensifier to ~ 14 µm.  
The decrease in tetracaine binding caused by the incorporation of cholesterol into 
the lipid bilayers could be related to the increase in the lipid packing density/the decrease 
in the area per phospholipid induced by cholesterol.57-59 This condensing effect of 
cholesterol has been previously reported for several lipid + cholesterol binary mixtures 
that exhibit a lower area per molecule compared to the average molecular areas of the 
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lipid and cholesterol alone.53,60,61  In particular, Kim and coworkers obtained a maximum 
decrease in the average area of DPPC in the so - lo phase coexistence region in a binary 
mixture of DPPC and 30 mol % cholesterol at 20°C.57 Hung et al. also observed a 
reduction in DMPC lipid area per molecule when the lipid is in the lo-ld phases for DMPC 
and 30 mol % cholesterol at 30°C. Most likely, the more densely packed lipid bilayers 
created by the presence of cholesterol result in less tetracaine partitioning into the lipid 
bilayers. Additionally, cholesterol is known to reside in the hydrophobic core of the lipid 
bilayer with the hydroxyl group staying close to the lipid ester carbonyl head group.62 
Evidence from an NMR study showed that tetracaine is located closer to the interfacial 
region of DMPC containing 30 mol % cholesterol (in the lo -ld phases) as compared to 
pure DMPC (lc).10 This indicates that cholesterol occupies empty space between the lipids 
and could exclude tetracaine from the lipid bilayer resulting in a decrease in tetracaine 
binding. 
One of the models which have been proposed to explain the condensing effect is 
the formation of a stoichiometric cholesterol and lipid complex.53,63 In the condensed 
complex, the lipid acyl chains are more ordered as the interaction between cholesterol 
and the acyl chains facilitates the extension of the acyl chains adjacent to cholesterol 
indicated by an increase in the membrane thickness,60,64 and a decrease in the number of 
gauche rotamers along the acyl chains.65 The ordering effect is much more significant in 
saturated lipids than in unsaturated lipids as the proximity between the acyl chains and 
cholesterol facilitate the interaction between cholesterol and the lipids. In the unsaturated 
lipid DOPC, the cis double bond configuration between C-9 and C-10 forms a bend of 30 
degrees in the aliphatic chains, leading to a conformational mismatch in contact with 
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cholesterol.66 Therefore, the ordering effect of cholesterol on DOPC is much less than 
that on saturated lipids (DMPC, DPPC).66,67 This explains why the effect of cholesterol 
on tetracaine binding to DOPC is insignificant as compared to DMPC. This behavior is 
further supported by a simulation study performed by Martinez-Seara and coworkers that 
showed that the ordering effect caused by cholesterol is minimized for DOPC but 
maximized for fully saturated 1,2-distearoyl-sn-glycero-3-phosphocholine DSPC (18:0, 
same chain length with DOPC).68 In the case of the mixed-chain SOPC lipid that contains 
a saturated sn-1 chain and a monounsaturated sn-2 chain, an intermediate behavior 
between the fully saturated lipid (DMPC) and di-unsaturated lipid DOPC was observed in 
the present study. This observation is supported by recent molecular dynamics 
calculations that showed that the increase in the lipid bilayer thickness caused by the 
incorporation of 20 mol % cholesterol is greatest for DSPC, moderate for SOPC and 
lowest for DOPC, as compared to the pure lipid systems.69 This study also demonstrated 
that cholesterol increases the order parameter S, which is used to quantify the ordering of 
the lipid acyl chain, in the order of DOPC < SOPC < DSPC.69 
A reduction in the Γmax of tetracaine upon the addition of 28 mol % cholesterol 
was observed for all the lipids, as listed in Tables 6.2 and 6.4. However, this reduction is 
not as significant as the decrease in Ka. In the presence of cholesterol, the Γmax of 
tetracaine in the unsaturated lipids DOPC and SOPC is much higher than that in the 
saturated lipid DMPC, confirming that the lipid packing in the membrane is the 















Table 6.4 Maximum surface excess of tetracaine in lipid bilayers containing 28 mol 
 % cholesterol at different temperatures. 
Lipid bilayer 
Γmax × 1012 (molecule/cm2) 
18°C 27°C 46°C 
DOPC + CHO 9.60 ± 0.16 7.02 ± 0.08 8.23 ± 0.16 
SOPC + CHO 8.39 ± 0.25 7.82 ± 0.16 7.34 ± 0.32 
DMPC + CHO N.A. 4.60 ± 0.24 5.24 ± 0.40 
DPPC + CHO N.A. N.A. N.A. 
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6.3.3 Thermodynamics of Tetracaine Binding  
 In addition to providing information about the binding affinity and maximum 
surface excess of tetracaine in lipid bilayers, the data presented here can also be used to 
determine the thermodynamics of the binding process. The van't Hoff plot shown in 
Figure 6.11 was used to determine the enthalpy (slope) and entropy (intercept) for 
tetracaine binding to the lipid bilayers. These values are given in Table 6.5 in addition to 
the calculated free energy. As seen in Table 6.5, the binding of tetracaine to pure DOPC 
and SOPC as well as DOPC containing 28 mol % cholesterol (DOPC + CHO) is 
associated with a large negative change in enthalpy (∆H) with values ranging from -32 to 
-34 kJ/mol. This can be attributed to the van der Waals interactions of the nonpolar 
portion of the drug with the hydrophobic region of the lipid bilayer where tetracaine 
inserts relative to the aqueous solution phase species.70,71 The change in entropy (∆S) is 
much smaller (-26 to -33 J/mol K) most likely due to the competing processes of 
desolvation of tetracaine upon insertion into the membrane (increase in S) and the 
ordering of water at the interface of the lipid bilayer (decrease in S) due to the presence of 
the positive charge on tetracaine. It has been reported that the water molecules at the 
air/water interface become more ordered, i.e., more hydrogen bonded with icelike 
structure in the presence of charged surfactants at the interface.72 The charged surfactants 
create a large electrostatic field which induces the alignment of the water at the 
interface.72 Similarly, the presence of the protonated tetracaine in the lipid bilayer could 
increase the surface potential, thus facilitating the ordering of the water at the interface. 
The significant contribution from ∆H to the free energy (∆G ~ -23 kJ/mol) indicates that 
the binding of tetracaine to the lipid bilayers is largely enthalpy-driven. This finding is 
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Figure 6.11 Van't Hoff plot for tetracaine binding to various lipid components: DOPC 
(filled circles), DOPC + 28 mol % cholesterol (open circles), SOPC (filled squares), 
SOPC + 28 mol % cholesterol (open squares), DMPC (filled triangles), DMPC + 28 mol 
% cholesterol (open triangles). The lines are the linear fits for the pure lipids (solid) and 
lipids containing cholesterol (dash): DOPC (black) and SOPC (grey).  
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Table 6.5 Free energy, enthalpy, and entropy of tetracaine binding to lipid bilayers 
 of various compositions. 
Lipid bilayer ∆G* (kJ/mol) ∆H (kJ/mol) ∆S (J/mol K) 
DOPC -23.6 ± 0.19 -34.2 ± 10.9 -33.4 ± 36.0 
DOPC + CHO -23.4 ± 0.21 -32.8 ± 14.4 -29.3 ± 47.5 
SOPC -23.8 ± 0.18 -31.9 ± 10.5 -25.6 ± 34.7 
SOPC + CHO -22.5 ± 0.18 -4.58 ± 0.89 59.7 ± 2.94 
       * determined at 27°C 
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consistent with previous studies which show that ΔH dominates the partitioning of small 
molecules into the lipid membranes.70,71,73-75   
 Interestingly, the thermodynamics of tetracaine binding to SOPC + CHO is 
entirely different. The enthalpic contribution is small (- 4.6 kJ/mol) while the entropy 
increases and becomes positive (~ 60 J/mol K). A similar decrease in the enthalpic 
contribution was reported by Rowe et al. for alcohols partitioning into lipid bilayers in 
the presence of cholesterol, which they attributed to the disruption of the lipid packing by 
the alcohol.76 As previously discussed, cholesterol increases the lipid packing density and 
order of the SOPC acyl chains greater than those of DOPC, and thus it is likely that 
tetracaine disrupts the more densely packed SOPC + CHO to a greater extent than DOPC 
+ CHO, causing a larger reduction in the van der Waals interactions between the lipid 
molecules. This results in a decrease in enthalpy when tetracaine binds to SOPC in the 
presence of cholesterol. The relatively large increase in entropy observed for tetracaine 
binding to SOPC + CHO may be explained by a disordering of the lipid acyl chains 
induced by tetracaine.10 The ordering of the lipid acyl chains by cholesterol is much more 
pronounced in SOPC relative to DOPC due to the close proximity of cholesterol to the 
saturated sn-1 chains of SOPC. Consequently, when tetracaine binds to the lipids the 
better ordered SOPC + CHO undergoes a larger entropic increase as the lipid transforms 
from a relatively ordered state into a disordered one. This larger entropy contribution 
indicates that the binding of tetracaine to SOPC + CHO is entropy-driven. 
 The enthalpy and entropy for tetracaine binding to DMPC and DMPC + CHO 
were not obtained in this work as the binding affinities at 18°C were not available. 
However, as previously mentioned it can be inferred that the binding affinities of 
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tetracaine to DMPC and DMPC + CHO at 18°C would be lower than at 27°C based on the 
data in Figures 6.8 and 6.9. This is consistent with an entropy-driven binding process as 
observed with SOPC + CHO. It is important to note that the previously discussed 
unsaturated lipids do not go through a phase transition over the temperature range 
presented here. The introduction of this phase change to DMPC and DMPC + CHO 
complicates the interpretation of the thermodynamic behavior beyond the scope of the 
present work. 
6.3.4 Neutral and Charged Tetracaine Binding  
 In the previous section, the interactions between tetracaine and lipid membranes 
were characterized at physiological pH (~ 7.4) where the drug is mostly positive charged 
(92% charged and 8% neutral). In this section, the interactions between tetracaine and the 
MLBAs were examined at different pHs in order to investigate the binding properties of 
different charge states of the drug, completely protonated and neutral. As the pKa of 
tetracaine in aqueous solution is 8.48,77 the pH of the tetracaine solution was adjusted to 
5.5 and 9.5 to ensure that tetracaine is either completely charged or neutral, respectively. 
It should be noted that tetracaine is neutral at pH 11; however, the solubility of tetracaine 
in PBS decreases above pH 9.5. For this reason, in order to investigate neutral tetracaine 
while avoiding solubility issues, a pH of 9.5 was used in this study, where 91% of 
tetracaine is in the neutral state. 
 The effect of the tetracaine charge state on its binding to lipid membranes was 
examined by comparing the relative SHG responses from 1.0 mM tetracaine in PBS at 
pH 9.5 and pH 5.5 binding to MLBAs composed of DOPC, SOPC, DMPC and DPPC 
bilayers with and without 28 mol % cholesterol. These experiments were conducted at 
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18°C, 27°C and 46°C and the positions of the lipid bilayer spots in the MLBAs are 
consistent with the previous section. As seen in Figure 6.12, the SHG intensity for bilayer 
bound tetracaine is much higher at pH 9.5 than pH 5.5. The control spot (1C) remains 
unchanged over the concentration range confirming the specific binding of tetracaine to 
the lipid bilayers. The normalized square-root of the SHG intensity, which is directly 
proportional to the amount of bound tetracaine in the bilayer, at 18°C, 27°C and 46°C is 
plotted in Figure 6.13, 6.14, and 6.15, respectively. 
 As seen in Figures 6.13a, 6.14a and 6.15a, the square-root of the SHG intensity 
from tetracaine binding to all lipid bilayer spots over the temperature range used in the 
study (18°C - 46° C) is significantly higher when the pH of the tetracaine solution is 9.5. 
This indicates that the neutral form of tetracaine (pH 9.5) binds to a greater extent to the 
lipids in both liquid-crystalline and solid-gel phases than the charged form (pH 5.5). The 
same behavior is observed for the lipids containing 28 mol % cholesterol (see Figures 
6.13b-6.15b). The favored binding of the neutral form of tetracaine to lipid bilayers 
relative to the charged species is attributed to the stronger hydrophobic interactions 
between the neutral drug and the hydrocarbon acyl chains of the lipids.10 The larger 
degree of binding observed for neutral tetracaine relative to the charged species is 
consistent with its higher partition coefficient (logPneutral = 3.32 ± 0.02 and logPcharged = 
2.11 ± 0.03).78 It has also been previously reported that the neutral form of tetracaine 
partitions more to the lipid bilayers in both fluid and solid-gel phases.10,77 This same 













Figure 6.12 The normalized SHG images of 1.0 mM tetracaine in PBS at pH: (1) 9.5 and 
(2) 5.5 binding to a multicomponent lipid bilayer array which contains the following lipid 
compositions: DOPC (1A, 1B, 2A, 2B); no lipids, control spot (1C) labeled by the white 
box; DOPC + 28 mol % cholesterol (2C); SOPC (3A, 3B); SOPC + 28 mol % cholesterol 
(3C); DMPC (4A, 4B); DMPC + 28 mol % (4C); DPPC (5A, 5B); DPPC + 28 mol % 
cholesterol (5C). The images were collected at 18°C (left), 27°C (middle) and 46°C 
(right). Each bilayer patch is approximately 400 µm × 400 µm.   
152 
 







Figure 6.13 Normalized square-root of the SHG intensity from 1.0 mM tetracaine binding 
at 18°C to various lipid components: DOPC, SOPC, DMPC and DPPC without 
cholesterol (a) and with 28 mol % cholesterol (b). The filled bar and the empty bar 
represent pH 9.5 and 5.5, respectively. The error bars depict the standard deviations from 











Figure 6.14 Normalized square-root of the SHG intensity from 1.0 mM tetracaine binding 
at 27°C to various lipid components: DOPC, SOPC, DMPC and DPPC without 
cholesterol (a) and with 28 mol % cholesterol (b). The filled bar and the empty bar 
represent pH 9.5 and 5.5, respectively. The error bars depict the standard deviations from 
at least two separate arrays with two spots for the pure lipids and one spot for the lipids 
containing cholesterol.  
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Figure 6.15 Normalized square-root of the SHG intensity from 1.0 mM tetracaine binding 
at 46°C to various lipid components: DOPC, SOPC, DMPC and DPPC) without 
cholesterol (a) and with 28 mol % cholesterol (b). The filled bar and the empty bar 
represent pH 9.5 and 5.5, respectively. The error bars depict the standard deviations from 
at least two separate arrays with two spots for the pure lipids and one spot for the lipids 
containing cholesterol.  
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6.3.5 Effect of Charged Lipids  
 The effect of charged lipids on tetracaine binding was also investigated in this 
study. At a pH of 7.4, 92% of tetracaine is positively charged; therefore, changing the 
surface charge of the lipid bilayer should cause a change in the partitioning of tetracaine 
at this pH by changing the electrostatic interactions between the drug and the lipid 
membrane. The surface charge of the lipid membrane was altered by incorporating either 
the negatively charged lipid DOPG or the positively charged lipid DOTAP into a 
zwitterionic DOPC lipid bilayer. The chemical structures of DOPG and DOTAP are 
shown in Figure 6.1. Figure 6.16 shows a representative image of 4.5 mM tetracaine 
binding to pure DOPC lipid bilayers as well as DOPC bilayers containing 10 mol% 
DOTAP, 20 mol % DOTAP, 10 mol % DOPG, and 20 mol % DOPG. Increasing the 
amount of DOTAP in the DOPC bilayer reduces the SHG intensity of the lipid spots 
while the intensity increases with amount of DOPG. The effect of these charged lipids on 
tetracaine binding was quantitatively evaluated by comparing the square-root of the SHG 
intensity of DOPC membranes containing DOPG and DOTAP relative to pure DOPC 
bilayers (Figure 6.17a). The data in Figure 6.17a are the average of four independent 
experiments. For each experiment, all bilayer compositions are triplicated in the array 
except for pure DOPC which is duplicated. It should be noted that the lipid array images 
were flat-field corrected and normalized by subtracting the image of a continuous DOPC 
bilayer in PBS pH 7.4 formed on the same substrate upon completion of the experiment 
(see section 6.2.5). The result of this subtraction was then divided by the image of a 
continuous DOPC bilayer in 4.5 mM tetracaine solution (in PBS pH 7.4). As seen in 
Figure 5.16a, the square-root of the SHG intensity was reduced by 10% and 17% relative 
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Figure 6.16 Normalized square-rooted SHG image of 4.5 mM tetracaine in PBS pH 7.4 
binding to a multicomponent lipid bilayer array which contains the following lipid 
compositions: DOPC + 20 mol % DOTAP (1A, 1B, 1C); DOPC + 10 mol % DOTAP 
(2A, 2B, 2C); DOPC (3A, 3B); no lipid, control spot (3C) labeled by the white box; 
DOPC + 10 mol % DOPG (4A, 4B, 4C); DOPC + 20 mol % DOPG (5A, 5B, 5C). Each 










Figure 6.17 Effect of charged lipids on tetracaine binding (a) Square-root of the SHG 
intensity from 4.5 mM tetracaine binding to various lipid components: DOPC+ 20 mol % 
DOTAP; DOPC + 10 mol % DOTAP; DOPC; DOPC + 10 mol % DOPG; and DOPC + 
20 mol % DOPG. The data are the average from the four independent arrays. (b) % 
change in square-root of the SHG intensity vs. surface charge density for: DOPC+ 20 mol 
% DOTAP; DOPC + 10 mol % DOTAP; DOPC; DOPC + 10 mol % DOPG; and DOPC 
+ 20 mol % DOPG.  
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to pure DOPC when 10 mol % and 20 mol % DOTAP were added, respectively. The 
decrease in tetracaine binding to in the presence of DOTAP is due to the electrostatic 
repulsion between positively charged tetracaine and positively charged DOTAP. In 
contrast, the presence of 10 mol % and 20 mol % DOPG resulted in attractive 
electrostatic interactions between the drug and the lipid membrane which increased the 
square-root of the SHG intensity relative to pure DOPC by 7% and 20%, respectively. 
The stronger partitioning of the charged form of tetracaine into negatively charged 
membranes has been previously observed with dimyristoylphosphatidic acid (DMPA) 
vesicles80 while a similar behavior was observed for another local anesthetic, dibucaine.37 
The repulsive interactions between charged tetracaine and cationic lipid membranes, 
however, have not yet been reported.  
The change in tetracaine binding to lipid bilayers caused by electrostatic 
interactions can be related to the charge density which arises from the presence of DOPG 
or DOTAP in the DOPC bilayer. Assuming a surface area of 70 Å2 for a single DOPC, 
DOPG and DOTAP lipids,34 the number of charges per unit area due to the incorporation 
of 10 and 20 mol % DOPG  in the DOPC bilayer was calculated to be - 2.29 and - 4.58 
µC/cm2, respectively. The calculated charge density is the same for DOPC bilayers with 
10 and 20 mol % DOTAP but with the opposite sign. Figure 6.17b shows the percentage 
change in the square-root of the SHG intensity versus the lipid charge density (µC/cm2). 
The linear correlation of the SHG data with the number of charges in the lipid bilayer 
illustrates the electrostatic interactions between the charged tetracaine and the charged 




    
 
6.4 Summary 
This work has demonstrated the use of counter-propagating SHG microscopy for 
the detection of drug-membrane interactions. The use of an MLBA allowed the effects of 
lipid physical state and cholesterol content on tetracaine binding to be investigated 
simultaneously. The results show that tetracaine binds more strongly into lipid bilayers in 
the liquid-crystalline phase as compared to the solid-gel phase. Cholesterol reduces the 
binding affinity of tetracaine to saturated DMPC and DPPC and mixed chain (saturated 
sn-1 and monounsaturated sn-2) SOPC while having no effect on di-unsaturated DOPC. 
Additionally, the maximum surface excess of tetracaine in the unsaturated lipids is 
greater than that in the saturated lipids. Furthermore, the binding of tetracaine into DOPC 
and SOPC bilayers is governed by enthalpic contributions while the entropy dictates the 
tetracaine binding to DMPC. The presence of cholesterol does not change the 
thermodynamics of tetracaine binding to DOPC but makes the binding of tetracaine to 
SOPC become entropy-driven. The neutral form of tetracaine binds to the lipids in both 
gel and liquid-crystalline phases to a greater extent than the charged species. The 
presence of the cationic DOTAP lipid lowers the amount of tetracaine binding to a DOPC 
bilayer while the anionic DOPG lipid increases tetracaine binding to a DOPC bilayer. 
The study presented in this chapter illustrates that SHG imaging can be used to directly 
image and quantitatively measure the association of a drug molecule into 
multicomponent lipid microarrays without using any extrinsic label. More interestingly, 
the drug concentration in the membrane is accessible with the use of SHG data and the 
knowledge of the drug partition coefficient. The signal/noise ratio in the SHG imaging 
experiments can be improved by using a SHG wavelength in better resonance with the 
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electronic transitions of tetracaine and/or using a more sensitive detector for image 
acquisition. Additionally, the acquisition time can be speeded up with the use of a high 
repetition rate laser. This work opens up further opportunities for the use of SHG imaging 
in high-throughput screening applications. 
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 The applications of nonlinear optical spectroscopies, second harmonic generation 
(SHG) and ultraviolet-visible sum frequency generation (UV-Vis SFG) in studying protein-
ligand and drug-lipid membrane interactions were described in this dissertation. The use of 
SHG and UV-Vis SFG allowed for the direct detection of these biomolecular interactions 
without the need for chemical modification. The general principles of SHG were presented in 
Chapter 2 with an emphasis on the counter-propagating geometry which allows for a better 
separation of the SHG beam from the fundamental beams. In Chapter 3, the counter-
propagating SHG technique was employed to study the binding properties of avidin, 
streptavidin, neutrAvidinTM and anti-biotin antibody to a biotinylated lipid. Protein binding 
assays were performed on a planar supported lipid bilayer of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) containing 4 mol % biotinylated-cap-1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (biotin-cap-DOPE). The equilibrium binding affinities of these biotin-
protein interactions were determined and correlated with the values reported in the literature 
validating the ability of SHG to be used an alternative technique to directly detect protein-
ligand binding at the lipid membrane surfaces. The relative energetic contributions for each 
protein to the biotinylated lipid ligand were also revealed. The results show that the binding 
affinities of avidin, streptavidin and neutrAvidinTM for biotin were all strengthened by 
protein-protein interactions but that stronger protein-protein interactions occur with 
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streptavidin making its binding the most energetically favorable. It was also shown that 
neutrAvidinTM has the highest degree of nonspecific adsorption to a pure DOPC bilayer as 
compared to avidin and streptavidin. Additionally, the biotin-binding affinity of anti-biotin 
antibody was found to be of the same order of magnitude as avidin, streptavidin and 
neutrAvidinTM. These findings provide important new insights into these biotin bound protein 
complexes, which are commonly used in several bioanalytical applications.  
 The background of SFG and the development of UV-Vis SFG were presented in 
Chapter 4. The deep UV wavelength of the UV-Vis SFG offers the ability to probe  π → π* 
and n → π* electronic transitions in a variety of biological species such as aromatic amino 
acids, peptides, proteins and aromatic/double bond containing drugs. In Chapter 5, UV-Vis 
SFG spectroscopy was used to measure the association of drugs to lipid membranes. Four 
different classes of drugs, exemplified by a nonsteroidal anti-inflammatory (ibuprofen), an 
antibiotic (azithromycin), a local anesthetic (tetracaine), and an antifungal (tolnafate), were 
examined. Drug association was measured on planar supported lipid bilayers (PSLBs) 
composed of DOPC. The equilibrium association constants of the drugs were obtained with 
the following order: ibuprofen < tetracaine < azithromycin< tolnafate. Additionally, the 
surface excess of the drugs in the lipid membrane was quantitatively determined using the 
combination of the bulk partition coefficient and the SFG measurements. The calculated limit 
of detection of the UV-Vis SFG technique was at the pg/cm2 level for these drugs and is 
comparable to that of fluorescence. Possessing great sensitivity and high surface specificity, 
UV-Vis SFG allowed for the direct detection of low molecular weight drug association into a 
lipid bilayer without any chemical modification and interference from solution phase species. 
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The study suggested that UV-Vis SFG is a powerful technique in measuring biomolecular 
interactions at surfaces. 
 The use of counter-propagating SHG to image the interactions between the local 
anesthetic tetracaine and a multicomponent planar supported lipid bilayer array in a label-free 
manner was presented in Chapter 6. The lipid bilayer arrays, prepared using a 3D continuous 
flow microspotter, allowed the effects of lipid phase and cholesterol content on tetracaine 
binding to be examined simultaneously. SHG images show that tetracaine has a higher 
binding affinity to liquid-crystalline phase lipids than to solid-gel phase lipids. The presence 
of 28 mol % cholesterol decreased the binding affinity of tetracaine to bilayers composed of 
the mixed chain lipid, 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC) and the 
saturated lipids 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC) while having no effect on DOPC. The maximum 
surface excess of tetracaine increases with the degree of unsaturation of the phospholipids 
and decreases with cholesterol in the lipid bilayers. The binding of tetracaine into DOPC and 
SOPC bilayers is an enthalpic process while entropy dominates tetracaine binding to SOPC 
with cholesterol as well as DMPC with and without cholesterol. The interactions between 
zwitterionic lipid bilayers and different charge states of tetracaine and between charged lipid 
bilayers with positively charged tetracaine were also presented in this chapter. It was found 
that the neutral form of tetracaine (pH 9.5) binds to the lipid bilayers with and without 
cholesterol to a greater extent than the charged form (pH 5.5). The presence of the positively 
charged lipid, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), in DOPC bilayer 
reduces the binding of tetracaine (pH 7.4) whereas binding to DOPC is enhanced by the 
presence of the negatively charged lipid, 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
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(DOPG). In addition to revealing the properties of tetracaine binding, this study also 
establishes SHG imaging as a sensitive technique to directly image and quantitatively 
measure the association of a drug to a multicomponent lipid bilayer array in a high-
throughput manner.  
This dissertation has shown that the nonlinear optical spectroscopy techniques, SHG 
and UV-Vis SFG, can be used to directly detect biomolecular interactions at the lipid bilayer 
surfaces without any chemical modification. Unlike mass based label-free techniques, the 
resonant enhancement in SHG and UV-Vis SFG, which is achieved by tuning the SHG or 
UV-Vis SFG frequency to approach to electronic transitions of the analytes at the surface, 
can be employed as an extremely sensitive spectroscopic probe to detect the binding of 
proteins and drugs to the lipid bilayers. Furthermore, the use of SHG imaging in combination 
with the lipid bilayer array created by the continuous flow microspotter allows for a rapid 
and systematic study of drug-lipid membrane interactions, illustrating the application of the 
technique as a high-throughput method. This dissertation has demonstrated the utility of SHG 
and UV-Vis SFG spectroscopy/imaging as valuable alternatives in sensing biomolecular 
interactions at lipid membrane surfaces and offering potential contributions as medical and 
pharmacological screening tools.   
 
 
 
 
 
